Innovative Vaccination: A New Era in Cancer Prevention

Authors:

Mehrdad Farrokhi
ERIS Research Institute

Nogol Ghalamkarpour
Isfahan University of Medical Sciences

Shadi Nouri
Arak University of Medical Sciences

Mahdi Babaei
ERIS Research Institute

Yasamin Rajabloo
Mashhad University of Medical Sciences

Mahtab Sattari
Shahid Beheshti University of Medical Sciences

Atousa Ghorbani
North Tehran Branch, Islamic Azad University

Vahid Jafari
University of Sevilla

Seyed Amir Hossein Mohammadzadeh Hosseini Moghri
Amol University of Special Modern Technologies

Ayda khalaj
Amol University of Special Modern Technologies

Zahra Hashempour
Shiraz University of Medical Sciences

Parnian Gourani
University of Rome Tor Vergata

Zahra Mogharari
Shahed University

Parsa Chaeibakhsh Langeroudi
I.M Sechenov First Moscow State Medical University

Ali Mansoursamaei
Shahroud University of Medical Sciences

Alireza Khanahmad
Kerman University of Medical Sciences

Alireza Mohammad Bigloo
Kerman university of medical sciences

Amirhossein Rigi
Shahid Beheshti University of Medical Sciences

Sara Moghimi
Tulane University

Mohammad Amin Hashemnejad
Alborz University of Medical Sciences

Elham Oveili
Azad Islamic University of Medical Science

Noushin Afshar Moghaddam
Shahid Beheshti University of Medical Sciences

Mohammad Eslami
Shahid Beheshti University of Medical Sciences

Saman Abdollahpour
Shahid Beheshti University of Medical Sciences

Farzaneh Kianifar
Iran University of Medical Sciences

Khadijeh Bagtash
Tehran University of Medical Sciences

Mohammad Hassan Zoofaghari

Tehran Medical Branch, Islamic Azad University

Fatemeh Kalaki Jouybari
Babol University of Medical Sciences

Pegah Babaheidarian
Iran University of Medical Sciences

Paria Babaahmadi
Shiraz University of Medical Sciences

Book Details:

Publisher: Kindle

Publication Date: February 2025

Language: English

Dimensions: 5 x 0.39 x 8 inches

ISBN-13: 979-8309132089

Contents

Chapters

1- INNOVATIVE VACCINATION FOR ENDOCRINE AND GASTROINTESTINAL CANCERS

Background

Cancer remains one of the leading causes of morbidity and mortality worldwide, with millions of new cases diagnosed each year. The complexity of cancer biology, characterized by genetic mutations, tumor heterogeneity, and the ability of tumors to evade immune detection, complicates treatment strategies. The landscape of cancer treatment is undergoing a significant transformation, with innovative vaccination strategies emerging as a promising approach, particularly for endocrine and gastrointestinal cancers. Gastrointestinal (GI) malignancies are among the most common malignancies and include colorectal, gastric, esophageal, hepatocellular, and pancreatic carcinomas. These cancers, particularly pancreatic and colorectal cancers, are notorious for their aggressive nature and poor prognosis, especially when diagnosed at later stages, making effective treatment challenging. Traditional therapies, such as chemotherapy and radiation, have limitations, including significant side effects and variable efficacy. In contrast, cancer vaccines aim to

harness the body's immune system to specifically target and eliminate cancer cells, offering a more tailored therapeutic option.

The concept of using vaccines to treat cancer is not new; however, recent advancements in immunology and biotechnology have revitalized interest in this field. Cancer vaccines can be broadly categorized into preventive and therapeutic types. Preventive vaccines, such as those for human papillomavirus (HPV) and hepatitis B virus (HBV), aim to prevent cancer development by targeting viral infections known to cause cancer. In contrast, therapeutic vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack tumor cells. Recent breakthroughs in vaccine technology, including peptide-based vaccines, dendritic cell vaccines, and mRNA vaccines, have shown promise in clinical trials, demonstrating the potential to improve patient outcomes and survival rates.

As we explore innovative vaccination strategies for gastrointestinal cancers, it is essential to consider the underlying mechanisms of these vaccines, their clinical applications, and the challenges that lie ahead. This review aims to provide a comprehensive overview of the current state of cancer vaccination, highlighting recent advancements and future directions in the field. By understanding the potential of these

innovative therapies, we can better appreciate their role in the evolving landscape of cancer treatment and the hope they offer to patients facing these challenging diseases.

Peptide-Based Vaccines

Peptide-based vaccines represent a significant advancement in cancer immunotherapy. These vaccines consist of short amino acid sequences corresponding to specific tumor-associated antigens (TAAs). By introducing these peptides into the body, the immune system can be trained to recognize and attack cancer cells expressing these antigens. The high specificity of peptide-based vaccines reduces the likelihood of off-target effects and autoimmune responses. Furthermore, their production is straightforward, and safety assessments have shown promising results. By stimulating a targeted immune response against TAAs on cancer cell surfaces, peptide-based vaccines have emerged as a potential therapeutic strategy for hepatocellular carcinoma (HCC).

For instance, in pancreatic cancer, which is notoriously aggressive and difficult to treat, peptide vaccines have shown promise in clinical trials. A study demonstrated that patients receiving a peptide vaccine targeting the cancer antigen MUC1 exhibited enhanced T-cell responses and improved overall survival compared to those receiving standard care alone.

This finding underscores the potential of peptide vaccines to not only stimulate the immune system but also improve clinical outcomes in patients with advanced disease.

Moreover, the combination of peptide vaccines with immune checkpoint inhibitors has emerged as a promising strategy. Checkpoint inhibitors, such as pembrolizumab and nivolumab, work by blocking proteins that inhibit T-cell activation, thereby enhancing the immune response against tumors. When used in conjunction with peptide vaccines, these agents can create a synergistic effect, leading to more robust and sustained immune responses.

Dendritic Cell Vaccines

Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that belong to the mononuclear phagocyte system and can activate naïve T cells against various host insults, including cancer. Dendritic cell vaccines are designed to enhance the body's immune response against cancer by loading dendritic cells with tumor antigens, which are then reintroduced into the patient. While DC vaccines have historically shown limited clinical efficacy in cancer treatment, the success of Sipuleucel-T and the emergence of immunomodulatory agents have renewed interest in this immunotherapeutic approach.

To maximize the clinical efficacy of DC vaccines, further optimization of vaccine strategies, including DC subtype, administration regimen, timing, and dosage, is essential. Additionally, combining DC vaccines with immune checkpoint blockade and/or anti-angiogenic therapies may enhance anti-tumor immune responses. Furthermore, incorporating tumor blood vessel-derived antigens into DC vaccines represents a promising approach to target the tumor vasculature and induce cytotoxic CD8+ T cell responses.

In gastrointestinal cancers, such as colorectal cancer, these vaccines are being investigated for their ability to enhance immune responses against tumor-specific antigens. Ongoing clinical trials are evaluating the efficacy of dendritic cell vaccines in combination with other immunotherapies, aiming to improve patient outcomes and expand treatment options.

mRNA Vaccine Technology

The success of mRNA vaccines during the COVID-19 pandemic has catalyzed interest in their application for cancer treatment. mRNA vaccines work by delivering genetic instructions to cells, prompting them to produce specific tumor antigens that stimulate an immune response. This technology offers several advantages, including the ability to rapidly design and produce vaccines

tailored to individual patients' tumor profiles. In preclinical studies, the efficacy and mechanisms of action of mRNA cancer vaccines are commonly evaluated through quantitative in vitro and in vivo assays. Thus far, mRNA vaccines have shown promising results across various animal models.

Early-phase clinical trials have shown promising results for mRNA vaccines in patients with gastrointestinal cancers. For example, a study involving an mRNA vaccine targeting a cancer antigen was conducted at Changhai Hospital, pioneering the world's first Phase I clinical pilot study investigating a personalized mRNA vaccine for advanced gastrointestinal cancer. This study aimed to evaluate the safety, tolerability, and efficacy of a personalized mRNA tumor vaccine encoding a novel antigen in patients with advanced gastrointestinal tumors. Preliminary findings suggest that personalized mRNA vaccines demonstrate a favorable safety profile. Additionally, the lipid nanoparticle-based mRNA cancer vaccine, mRNA-5671, which targets four KRAS mutations, is currently undergoing evaluation in a Phase I clinical trial. The mRNA vaccine therapeutic approach for KRAS-mutated colorectal cancer involves either monotherapy or combination therapy with pembrolizumab.

The potential synergy between mRNA vaccines and immunotherapies, such as checkpoint inhibitors or adoptive T-cell therapy, could offer

improved clinical outcomes for patients with common epithelial cancers. The flexibility of mRNA technology allows for the incorporation of multiple antigens, potentially enhancing the vaccine's effectiveness against heterogeneous tumors. As research continues, mRNA vaccines may become a cornerstone of cancer immunotherapy, particularly for difficult-to-treat gastrointestinal cancers.

Esophageal Cancer Vaccines

Esophageal cancer (EC) ranks as the sixth leading cause of cancer-related fatalities and the seventh most prevalent malignant tumor worldwide. In 2018, it was estimated that 509,000 deaths occurred among 572,000 new cases of EC. Currently, locally advanced EC is treated using a multidisciplinary approach, which includes neoadjuvant chemoradiotherapy followed by surgical intervention. Despite this standard treatment, a pathological complete response is achievable in only 29% of cases that undergo surgery after chemoradiotherapy, and the frequency of treatment-related adverse events during chemoradiotherapy, especially those graded as 3 or 4, remains high. Despite advancements in therapy, the long-term survival rates for individuals with locally advanced EC remain disappointing. Immunotherapy, which includes immune checkpoint blockade, adoptive T cell therapy, and cancer vaccination, has

recently been explored as a promising approach to improving survival rates for EC patients.

Conventional cancer vaccines primarily utilize antigens that are expressed both in normal human tissue and tumor tissue. However, tumor neoantigens are highly specific to tumors and possess remarkable immunogenicity, making them ideal targets for the development of cancer vaccines. A novel class of tumor immunotherapy, known as neoantigen vaccines, has the potential to trigger a robust and specific immune response while also producing lasting therapeutic effects. New York esophageal squamous cell carcinoma 1 (NY-ESO-1) belongs to the testis cancer gene family and is characterized by its strong immunogenic properties. Oshima et al. conducted a screening involving 1,969 patients across different cancer types and found that serum antibodies against NY-ESO-1 could serve as a specific biomarker for esophageal cancer. Subsequently, a phase I clinical trial was carried out by Wada et al. Eight patients with advanced esophageal cancer participated in the trial, receiving NY-ESO-1 protein as a vaccine. The researchers observed CD4+ T cell, CD8+ T cell, and antibody responses in 87.5% (7/8), 75.0% (6/8), and 87.5% (7/8) of the patients, respectively. However, despite the vaccination, all patients eventually experienced disease progression due to factors such as the growth of the primary tumor or metastasis to abdominal or paratracheal lymph

nodes.

A phase I dose-escalation study involving a two-dose group showed that the cholesteryl pullulan (CHP)-NY-ESO-1 vaccine is safe and capable of inducing immune responses in patients with advanced metastatic esophageal cancer. Compared to the 100 mg dose cohort, the cohort receiving a 200 mg dose generated a more robust immune response and exhibited improved survival rates. Additionally, NY-ESO-1-positive patients with esophageal squamous cell carcinoma participated in a phase II comparative trial of the CHP-NY-ESO-1 vaccine, receiving neoadjuvant chemotherapy before surgery. However, there was no notable survival benefit observed between the untreated control group and the CHP-NY-ESO-1 vaccine group.

Numerous studies have demonstrated that cytotoxic T-cell stimulation and immune response initiation follow the administration of neoantigen vaccines. Nevertheless, achieving adequate and lasting immune responses with antitumor vaccines remains a challenging task. Rosenberg et al. proposed that tumor tissue cells may employ various mechanisms to evade the immune system, including inadequate expression of tumor antigens, T cells becoming “tolerized,” the tumor's production of local immunosuppressive factors, or a reduction in T cell receptor signaling, among other factors.

In contrast to traditional peptide vaccines, mRNA

vaccines represent a type of genetic vaccine that has the potential to trigger a robust immune response. By studying a new chimeric mRNA-loaded dendritic cell (DC) vaccine ex vivo, Forghanifard et al. established the vaccine's ability to provoke an effective immune response and promote cytotoxicity against esophageal carcinoma. While this research was conducted at the preclinical level, it opened a novel avenue for employing dendritic cell-based vaccines in the immunotherapy of EC.

Radiation and chemotherapy are essential treatment options for patients with EC. These treatments stimulate the generation of tumor antigen-specific effector cells by encouraging tumors to release antigens within the tumor environment. A phase I clinical trial that applied chemoradiation therapy alongside a multiple-epitope peptide vaccine showed promising results. Specifically, a complete response was observed in six of eleven patients, with four of those who responded completely benefiting from long-term survival. Integrating immunotherapy with chemoradiotherapy is now emerging as an innovative treatment strategy.

Despite the extensive number of clinical trials conducted for cancer vaccines targeting esophageal squamous cell carcinoma, peptide-based vaccines for this condition have yet to be licensed for clinical use. However, previous

studies have identified novel immunogenic cancer antigens such as TTK protein kinase, lymphocyte antigen 6 family member K (LY6K), insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), and NUF2, a component of the NDC80 kinetochore complex. These immunogenic cancer antigens (ICAs) are highly and frequently expressed among different esophageal cancer antigens, and their demonstrated association with survival and cell proliferation in esophageal squamous cell carcinoma highlights their potential as targets for cancer vaccines. Three human leukocyte antigen-A24-restricted, immune-dominant peptides derived from TTK, IGF2BP3, and LY6K have been identified. In a phase I/II clinical trial for HLA-A24, patients with advanced esophageal squamous cell carcinoma who exhibited an immune response to vaccination showed improved prognosis compared to those who did not experience an immune response.

Gastric Cancer Vaccines

Numerous clinical trials have evaluated cancer vaccines in patients with gastric cancer, including two peptide-based vaccines targeting vascular endothelial growth factor receptors 1 and 2 in patients with advanced gastric cancer. These vaccines, when combined with chemotherapy (S-1 plus cisplatin), were shown to effectively inhibit vascular endothelial growth and improve overall survival times. Despite these promising results,

several challenges persist in the development of effective cancer vaccines, including the identification of tumor-specific antigens and the optimization of vaccine delivery methods.

Colorectal Cancer Vaccines

In recent decades, significant technological advancements and sustained investments have led to the development of various colorectal cancer (CRC) vaccine platforms, including DNA vaccines, RNA vaccines, peptide vaccines, dendritic cell vaccines, and viral vector vaccines. While most of these immunotherapies are in the early clinical stages for colorectal cancer, their success in other cancer types suggests promising potential. DNA mismatch repair protein deficiencies can lead to microsatellite instability, which results in mutated peptide antigens. These mutated antigens are considered highly immunogenic, making them attractive targets for cancer vaccines. However, clinical trials of therapeutic vaccines for colorectal cancer, employing various delivery methods, have yielded mixed results.

Challenges in Cancer Vaccination

Despite the promising advancements in cancer vaccination, numerous challenges remain. One of the primary hurdles is the identification of appropriate tumor antigens that can elicit strong and specific immune responses. Tumors

often exhibit a high degree of heterogeneity, which complicates the search for universal targets. Additionally, the immunosuppressive tumor microenvironment can inhibit vaccine effectiveness, thereby limiting their ability to generate robust immune responses.

Another challenge is the need for personalized approaches to vaccination. Since each patient's tumor may express different antigens, tailored vaccine formulations are often required. This personalization complicates the manufacturing and regulatory processes, potentially delaying the availability of effective treatments.

Future Directions

Looking toward the future, cancer vaccination shows immense promise. Ongoing research is focused on optimizing vaccine formulations, improving delivery methods, and discovering novel antigens. Combination therapies that integrate vaccines with other treatment modalities, such as chemotherapy, targeted therapy, and immunotherapy, are also being explored.

Furthermore, advancements in technology, particularly artificial intelligence and machine learning, may aid in the identification of new tumor antigens and the development of more effective vaccines. These technologies can analyze large datasets to uncover patterns

and correlations that may not be immediately apparent through traditional research methods.

Conclusion

Innovative vaccination strategies offer a transformative approach to the treatment of gastrointestinal cancers. By harnessing the immune system's power, these vaccines have the potential to provide more effective and personalized therapies. As research progresses, it is essential to address the challenges associated with cancer vaccination to fully realize their potential in clinical practice. With continued innovation and collaboration, cancer vaccines may play a pivotal role in improving patient outcomes and offering new hope to those affected by these challenging diseases.

2- INNOVATIVE VACCINATION FOR PEDIATRIC CANCERS

Background

Pediatric cancer remains a leading cause of childhood mortality. However, its prognosis has significantly improved over the past few years, with the average overall survival rate increasing to 83%. Pediatric cancers, though relatively rare compared to adult malignancies, remain a significant cause of morbidity and mortality in children worldwide. Advances in chemotherapy, radiotherapy, and surgery have led to improved survival rates; however, these treatments often come with severe long-term side effects, including secondary malignancies, organ damage, and reduced quality of life. This has driven the search for innovative and less toxic therapeutic strategies, among which cancer vaccines have emerged as a promising approach.

Cancer vaccines are designed to stimulate the immune system to recognize and eliminate malignant cells, offering a targeted treatment strategy that minimizes harm to normal tissues. Unlike conventional therapies, which often lead to systemic toxicity, cancer vaccines have the potential to provide durable immunity with fewer adverse effects. Recent advancements

in immunotherapy, particularly in vaccine-based approaches, have shown promising results in various pediatric cancers, including neuroblastoma, leukemia, brain tumors, and sarcomas.

This paper explores the different types of innovative vaccination strategies under development for pediatric cancers, recent advancements in research, challenges faced in clinical application, and future directions in the field.

Vaccination Types for Pediatric Cancers

Treatment approaches for pediatric cancer are occasionally faced with refractory cases that cannot be effectively treated with radiation, surgery, or chemotherapy. Furthermore, many children suffer from aggressive malignancies such as central nervous system (CNS) tumors, which are among the most severe childhood malignancies, often exhibiting resistance to both medical and surgical treatments. Immunotherapy has emerged as a promising therapeutic option for a wide range of cancer patients. Here, we highlight therapeutic approaches in pediatric oncology, including dendritic cell vaccines, peptide vaccines, and, more recently, monoclonal antibody (mAb) and chimeric antigen receptor (CAR) T-cell therapy, which have been approved for treating pediatric

patients. While these approaches have received FDA approval for pediatric use, further research is still required to evaluate their efficacy and long-term benefits for pediatric cancer patients.

Dendritic Cell Vaccines

Dendritic cells (DCs) are antigen-presenting cells (APCs) responsible for presenting antigens to prime CD4+ and CD8+ T cells and for producing cytokines. Despite the advantages of DC-based vaccines, they also present challenges, including high costs associated with cell enrichment or isolation, the complexity of ex vivo stimulation procedures, inadequate cell numbers, and limitations in cell activation. Notably, the first FDA-approved cancer vaccine, sipuleucel-T (Provenge), is a DC-based vaccine for prostate cancer.

Data from phase I/II clinical trials indicate that DC-based vaccines exhibit minimal toxicity in children with various types of cancer. A phase II trial evaluating an autologous tumor lysate-pulsed DC vaccine in pediatric patients with recurrent or metastatic sarcomas demonstrated a significant improvement in overall survival (OS) in the DC-vaccinated group. Research conducted by Benitez-Ribas involved a phase I study of a DC vaccine pulsed with autologous tumor cell-line lysate as the antigen, serving as a source of T-cell (CD4+) epitopes to enhance the immune response.

This study, conducted in nine pediatric patients with newly diagnosed diffuse midline glioma (DMG)—a highly invasive and universally fatal subgroup of pediatric high-grade gliomas (HGG)—demonstrated specific anti-cancer immune activity in eight out of nine patients.

Peptide Vaccines

Peptide-based vaccines generally consist of one or multiple synthetic peptides containing cancer-specific antigens, often combined with adjuvants to enhance the immunogenicity of the peptide antigen. Multi-peptide vaccines targeting conserved cancer antigens have been investigated in pediatric clinical trials.

In a phase I clinical trial conducted by Kushner et al., 15 pediatric patients with high-risk neuroblastoma received a vaccine containing the neuroblastoma-associated antigens GD2 and GD3, along with an adjuvant (OPT-821). The results showed no dose-limiting toxicities, and 12 out of 15 children exhibited an antibody response against GD2 and GD3, highlighting the potential efficacy of this vaccine approach.

DNA and RNA-Based Vaccines

DNA and RNA-based cancer vaccines utilize genetic material encoding tumor antigens to stimulate an immune response. These vaccines are designed to be taken up by host cells, which

then produce tumor antigens that trigger immune activation.

The recent success of mRNA vaccines in infectious diseases, such as COVID-19, has renewed interest in their application for cancer treatment. Preclinical studies have demonstrated that mRNA vaccines encoding pediatric tumor antigens, such as GD2 for neuroblastoma and WT1 for leukemia, can induce robust antitumor responses in animal models. Clinical trials are currently underway to evaluate their efficacy in pediatric patients.

Oncolytic Virus Vaccines

Oncolytic viruses are genetically engineered viruses that selectively infect and destroy cancer cells while simultaneously stimulating an immune response. These viruses can be designed to express tumor antigens, enhancing their ability to trigger immune recognition.

In pediatric oncology, oncolytic viruses such as herpes simplex virus (HSV), adenovirus, and vesicular stomatitis virus (VSV) have been explored as potential therapeutic agents. Clinical trials have reported encouraging results in patients with neuroblastoma, sarcomas, and brain tumors, showing improved immune activation and tumor regression. However, challenges such as immune evasion and potential toxicity must be addressed to optimize their therapeutic potential.

Tumor Lysate-Based Vaccines

Tumor lysate vaccines use fragments of tumor cells to stimulate an immune response against multiple tumor antigens simultaneously. This approach offers the advantage of targeting a broader range of tumor antigens, reducing the risk of immune escape.

For pediatric cancers, tumor lysate vaccines have been tested in patients with brain tumors and neuroblastoma. Some clinical trials have shown prolonged progression-free survival and improved immune responses when these vaccines are combined with immune-stimulating adjuvants or checkpoint inhibitors.

Pediatric Cancer Immunotherapy

Immunotherapy for pediatric cancers includes monoclonal antibody (mAb) therapy, which has been successfully utilized for pediatric hematologic malignancies. One of the earliest mAbs used in oncology, Rituximab, was the first mAb approved for clinical application in 1997 for adult patients. It is a CD20-targeting antibody used in the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma (NHL).

In pediatric NHL patients, the addition of rituximab to chemotherapy improved the one-year event-free survival (EFS) rate from 81.5% to 94.2%. Additionally, anti-CD22 mAbs have been

explored in both adult and pediatric B-cell acute lymphoblastic leukemia (ALL), demonstrating promising success. Furthermore, anti-GD2 mAb therapy is currently being utilized in neuroblastoma and other GD2-positive pediatric cancers.

Chimeric antigen receptor T-cell (CAR-T) therapy has also shown remarkable potential in pediatric hematologic malignancies, with CD19 CAR-T, GD2 CAR-T, and CD22 CAR-T emerging as some of the most promising approaches. In a phase I study investigating GD2 CAR-T therapy in relapsed neuroblastoma, two patients achieved stable remission. Similarly, HER2 CAR-T therapy has been explored in pediatric solid tumors, including osteosarcoma. A phase I/II trial of HER2 CAR-T therapy in osteosarcoma (NCT00924287) reported no dose-limiting toxicities, suggesting its safety in pediatric patients.

CTLA-4, an immune checkpoint, plays a crucial role in regulating autoimmunity by suppressing T-cell activation through its interaction with CD80/86 on dendritic cells (DCs). Recent phase I research (NCT01445379) involving pediatric patients with solid tumors, such as melanoma, demonstrated that CTLA-4 blockade led to an increase in cytotoxic T-cell activation, suggesting its potential as an effective immunotherapeutic strategy.

In conclusion, the field of pediatric cancer

immunotherapy, particularly vaccine-based approaches, continues to evolve with promising results. Ongoing research and clinical trials are essential to further optimize these treatments, improve survival rates, and enhance the quality of life for pediatric cancer patients.

3- INNOVATIVE VACCINATION FOR SKIN CANCERS

Background

Skin cancers, including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC)—both classified as nonmelanocytic skin cancers (NMSC), as well as melanoma—are among the most prevalent cancers worldwide. Each year, more than one million new cases are diagnosed, and the incidence of these cancers has been steadily rising over the past decade. This increasing trend underscores the need for better understanding and strategies to both prevent and treat skin cancer. The rise in skin cancer cases over several decades can be attributed to increased ultraviolet (UV) radiation, an aging population, behavioral changes such as tanning, immunodeficiency, and human papillomavirus (HPV) infection. Although skin cancers other than melanoma, such as NMSCs, are more common, melanoma remains the leading cause of skin cancer-related deaths due to its aggressive nature and high metastatic potential.

Current treatment options, such as surgical excision, radiotherapy, and systemic therapies —particularly immune checkpoint inhibitors targeting programmed cell death protein 1

(PD-1) and its ligand (PD-L1)—have proven highly effective, particularly in managing advanced-stage melanoma. However, despite their significant efficacy, these therapies are often limited by immune-related adverse effects, tumor recurrence, and resistance in certain patients. This highlights the need for innovative approaches that could improve patient outcomes and sustain anti-tumor responses over time.

In the realm of immunotherapy, therapeutic cancer vaccines have emerged as a promising strategy. Unlike prophylactic vaccines, which aim to prevent infections (such as the HPV vaccine), cancer vaccines are designed to stimulate immune responses targeting tumor-associated antigens (TAAs) or neoantigens. This distinction underscores the unique role of cancer vaccines in the broader context of cancer treatment development. These vaccines leverage the body's immune system to activate cytotoxic T lymphocytes (CTLs) and enhance immunological memory, offering the potential for lasting tumor control. The goal of therapeutic cancer vaccines is to promote tumor regression, eliminate minimal residual disease, establish long-term antitumor immunity, and minimize adverse effects.

The development of skin cancer vaccines has benefited from the skin's distinct immunological features. The skin is rich in antigen-presenting cells (APCs), including dendritic cells

and Langerhans cells, making it an accessible and highly active site for initiating antitumor immune responses. Advances in technology have enhanced various vaccine platforms, such as DNA, peptide-based, dendritic cell (DC), and mRNA vaccines, which are designed to target specific tumor-associated antigens or neoantigens in skin cancers. Among these, mRNA vaccines have shown remarkable adaptability and robust immunogenicity, especially when combined with immune checkpoint inhibitors. Clinical trials are currently evaluating the potential of these vaccine platforms. For instance, mRNA-based neoantigen vaccines used alongside checkpoint inhibitors have demonstrated improved progression-free survival and reduced recurrence rates in melanoma patients. Likewise, dendritic cell vaccines have been shown to enhance tumor-infiltrating lymphocytes and promote tumor regression. However, broader application of these vaccines is hindered by challenges such as identifying relevant neoantigens, the complexities of rapid vaccine manufacturing, and difficulties in detecting clinically significant immune responses.

To address these challenges, it is essential for vaccines to be incorporated into multimodal treatment regimens, and delivery methods like nanoparticles and microneedles must be optimized to enhance immune responses. This chapter critically examines the scientific and

clinical advances in skin cancer vaccines, with a focus on the mechanisms, platforms, and translational potential. The aim is to explore how innovative vaccines might transform skin cancer treatment by addressing current challenges and shaping future directions in this evolving field.

Recent advancements in innovative vaccination strategies for skin cancer have focused on enhancing immune responses and targeting specific cancer antigens. One promising approach involves the induction of skin-resident memory CD8+ T cells through intradermal vaccination, which has shown strong protection against melanoma by suppressing tumor growth and infiltrating tumors.

Another approach uses transcutaneous cancer vaccines, leveraging the skin's dendritic cells to induce antigen-specific immune responses. This technique has been refined through the use of reverse micellar carriers to enhance antigen delivery, resulting in substantial tumor growth suppression. Microneedle patches containing tumor lysate and melanin have also shown promise in boosting the efficacy of antitumor vaccines by facilitating heat production and improving antigen uptake by dendritic cells. Additionally, the development of peptide-based vaccines for melanoma is currently under investigation. These vaccines aim to enhance immunogenicity by incorporating synthetic

modifications, adjuvants, or delivery systems.

DNA-based vaccines are being explored for melanoma, offering benefits such as stability and the ability to elicit both cellular and humoral immune responses. These vaccines are designed to encode multiple melanoma antigens and incorporate molecular adjuvants to further enhance immune responses. Moreover, transcutaneous delivery of DNA and mRNA vaccines is being studied for its ability to induce robust immune responses by targeting skin dendritic cells.

Personalized mRNA vaccines represent a revolutionary strategy for melanoma treatment. These vaccines are tailored to target specific mutations within an individual's tumor, increasing the chances of a successful immune response. Designing vaccines to match the genetic profile of a patient's tumor offers a more precise and focused therapeutic approach, which is especially important given melanoma's high tumor mutational burden.

Pediatric Cancers: A Brief Overview

Pediatric cancers differ from adult cancers in terms of their biological characteristics, tumor microenvironment, and response to treatment. The most common types of pediatric malignancies include:

Leukemias (Acute lymphoblastic leukemia [ALL]

and acute myeloid leukemia [AML])
Brain and central nervous system (CNS) tumors (Medulloblastoma, gliomas)
Neuroblastoma
Wilms tumor (kidney cancer)
Sarcomas (Osteosarcoma, Ewing sarcoma)
Lymphomas (Hodgkin's and non-Hodgkin's lymphoma)
While survival rates for some pediatric cancers have improved significantly with conventional therapies, high-risk and relapsed cases remain a challenge. Immunotherapy, particularly vaccination strategies, has gained attention as a potential alternative or adjunct to existing treatment modalities.

Types of Cancer Vaccines in Pediatric Oncology

Several vaccination strategies are being investigated for their potential to treat pediatric malignancies. These include:

Peptide-Based Vaccines

Peptide-based vaccines utilize short amino acid sequences derived from tumor-associated antigens to stimulate an immune response. These vaccines work by activating cytotoxic T lymphocytes (CTLs), which recognize and attack cancer cells expressing the corresponding antigen.

Key Target Antigens

GD2 (Neuroblastoma)
Wilms tumor protein 1 (WT1) (Leukemia, brain tumors)
Survivin (Multiple pediatric cancers)
Melanoma-associated antigen (MAGE) family proteins
Several clinical trials have demonstrated that peptide-based vaccines can elicit strong immune responses in pediatric cancer patients. However, their efficacy often depends on the patient's major histocompatibility complex (MHC) type, limiting their broad applicability.

Dendritic Cell (DC) Vaccines

Dendritic cells are antigen-presenting cells that play a crucial role in initiating and regulating immune responses. DC vaccines involve isolating these cells from patients, loading them with tumor antigens ex vivo, and then reinfusing them to elicit a targeted immune response.

Clinical Applications in Pediatric Cancers

DC vaccines have been tested in neuroblastoma, gliomas, and sarcomas.
Studies have shown that DC vaccines loaded with tumor lysates or synthetic peptides can enhance T-cell responses and improve survival rates.
The process is complex and costly, but it offers a personalized approach to cancer immunotherapy.

DNA and RNA-Based Vaccines

DNA and RNA-based vaccines utilize genetic material encoding tumor antigens to stimulate an immune response. These vaccines are designed to be taken up by host cells, which then produce tumor antigens, triggering immune activation.

Advantages

Long-term immune memory
Low risk of inducing autoimmunity
Can be rapidly developed and modified for different antigens

Clinical Applications in Pediatric Oncology

mRNA vaccines have shown promise in neuroblastoma by encoding the GD2 antigen.
DNA vaccines targeting WT1 and survivin have been tested in leukemia models.
Early-phase trials indicate that DNA/RNA vaccines can induce durable antitumor immunity, especially when combined with immune checkpoint inhibitors.

Oncolytic Virus Vaccines

Oncolytic viruses are genetically engineered to selectively infect and destroy cancer cells while simultaneously stimulating an immune response. These viruses can also be modified to express tumor antigens, enhancing their ability to trigger

immune recognition.

Promising Oncolytic Viruses in Pediatric Cancers

Herpes simplex virus (HSV) for gliomas
Vesicular stomatitis virus (VSV) for osteosarcoma
Adenoviruses for neuroblastoma
Recent clinical trials suggest that oncolytic viruses not only destroy tumor cells but also stimulate systemic immunity, making them a potential game-changer in pediatric oncology.

Tumor Lysate-Based Vaccines

Tumor lysate vaccines use fragments of tumor cells to stimulate an immune response against multiple tumor antigens simultaneously. This approach offers the advantage of targeting a broader range of antigens, reducing the risk of immune escape.

Clinical Studies

Glioma vaccines using tumor lysates have shown prolonged progression-free survival in some pediatric patients.
Neuroblastoma trials indicate that tumor lysate vaccines combined with immune adjuvants enhance immune activation.

Recent Advances in Pediatric Cancer Vaccination

Neuroblastoma Vaccination Strategies

Neuroblastoma, a highly aggressive pediatric malignancy, has been a major focus of vaccine research. Several vaccine strategies have demonstrated encouraging results:

GD2-based peptide vaccines have shown promise in early trials.

DC vaccines loaded with neuroblastoma tumor lysates have prolonged survival in some patients.

Oncolytic viruses expressing GD2 antigens are under investigation for their ability to induce tumor-specific immune responses.

Leukemia Vaccines

Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) remain leading causes of childhood cancer mortality. Innovative vaccination strategies include:

DNA vaccines encoding WT1 and PRAME antigens, showing strong immune responses in preclinical models.

Combination of leukemia vaccines with CAR-T cell therapy, enhancing long-term remission rates.

Brain Tumor Vaccination Approaches

Pediatric brain tumors, such as medulloblastoma and high-grade gliomas, present unique challenges due to the blood-brain barrier.

However, recent studies have shown:

DC vaccines using glioma tumor lysates have resulted in improved progression-free survival.

Peptide vaccines targeting glioma-specific antigens have shown immune activation in early trials.

Oncolytic viruses engineered to cross the blood-brain barrier are under investigation.

Challenges in Implementing Cancer Vaccination in Pediatrics

Despite promising advancements, several challenges remain:

Tumor Heterogeneity – Pediatric cancers exhibit genetic diversity, making it difficult to develop universal vaccines.

Immune Evasion – Tumors can suppress immune responses, necessitating combination therapies.

Limited Clinical Data – Small patient populations make it difficult to conduct large-scale trials.

Regulatory and Ethical Concerns – Pediatric vaccine trials require stringent oversight.

Cost and Accessibility – Advanced vaccine technologies remain expensive and may not be widely available.

Future Directions in Pediatric Cancer Vaccination

Combination Therapies

Cancer vaccines combined with checkpoint

inhibitors (e.g., PD-1/PD-L1 inhibitors) to enhance immune responses.
Vaccine-CAR-T cell therapy hybrids for hematologic and solid tumors.

Personalized Vaccination Approaches

Neoantigen-based vaccines tailored to individual patient tumor profiles.
Artificial intelligence-driven vaccine design to identify optimal antigen targets.

Expanded Clinical Trials

International collaborations to conduct large-scale vaccine trials in pediatric cancers.
Incorporation of vaccine strategies in standard treatment protocols for pediatric oncology.

Global Accessibility Initiatives

Development of cost-effective vaccine technologies for low-resource settings.
Partnerships with governments and non-profits to expand vaccine availability.

Conclusion

Innovative vaccination strategies offer a promising avenue for improving pediatric cancer treatment outcomes. Advances in peptide-based, DC, DNA/RNA, oncolytic virus, and tumor lysate vaccines have demonstrated encouraging results in preclinical and clinical studies.

However, challenges such as tumor heterogeneity, immune evasion, and accessibility must be addressed. With continued research, investment, and collaboration, cancer vaccines may become a cornerstone of pediatric cancer treatment, providing safer and more effective alternatives to traditional therapies.

4- INNOVATIVE VACCINATION FOR BREAST AND LUNG CANCERS

Background

Overview of Breast and Lung Cancers as Leading Causes of Cancer-Related Mortality Worldwide

Breast cancer is the most common type of cancer among women, accounting for approximately one in ten newly diagnosed cancer cases and a significant proportion of cancer-related deaths worldwide. The risk factors for breast cancer are well understood, and mitigating these risks is essential for reducing the incidence of the disease. In Western countries, breast cancer is frequently detected through routine screening, often developing insidiously. In the absence of screening, it is commonly identified as a palpable lump. Treatment options for breast cancer vary based on the tumor's stage and type and may include surgery, radiation therapy, chemotherapy, and immunotherapy. Advances in these treatment modalities have significantly improved overall survival rates and patient-reported outcomes.

The breasts are paired glandular structures located superficially to the pectoralis major muscle, with

variations in size and density. They consist of lobules containing milk-producing cells, which are grouped into lobes interspersed with fat. Lactiferous ducts extend to the nipple, facilitating the discharge of milk and other fluids produced in the acini. The breast is supported by Cooper's ligaments, which anchor it to the underlying muscle tissue.

Although ductal carcinoma is the most common type of breast cancer, arising from the ductal epithelium, lobular carcinoma can also develop in the breast lobules. Several risk factors for breast cancer have been well documented. In Western nations, most breast cancers are detected through organized screening programs rather than through symptoms. However, in many developing regions, a breast lump or unusual nipple discharge remains the most common initial sign of the disease.

Bronchogenic carcinoma, commonly referred to as lung cancer, is a malignancy originating in the bronchi or lung tissues. In the United States, it is considered one of the deadliest forms of cancer. Since 1987, lung cancer has surpassed breast cancer as the leading cause of cancer-related deaths in women. Each year, approximately 225,000 new cases of lung cancer are diagnosed in the U.S., resulting in an estimated 160,000 deaths. Interestingly, lung cancer was relatively rare in the early 1900s. The subsequent dramatic rise in lung cancer incidence over successive decades has been

attributed to the increasing prevalence of smoking in both men and women.

Cancer is increasingly recognized as a complex systemic disease capable of adeptly evading immune responses through various sophisticated escape mechanisms. This ability of tumors to manipulate both the function and composition of the immune system creates a significant challenge for effective cancer treatment. The evolution of anti-cancer therapies has been characterized by the development of strategies that enhance both the efficacy and specificity of targeting malignant cells while minimizing damage to surrounding healthy tissues.

Among the diverse therapeutic modalities available today, immunotherapy stands out as a groundbreaking approach that harnesses the power of the immune system to combat cancer more effectively. The emergence of immune cell therapies has provided renewed hope to patients, particularly those with malignancies that are resistant to conventional treatment methods. A pivotal milestone in cancer treatment was reached in 2017 when the U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor T (CAR-T) cell therapies, Axicabtagene ciloleucel and Tisagenlecleucel, specifically designed to treat hematologic cancers. This landmark approval not only expanded treatment options for patients but also underscored the transformative potential of

immunotherapy in cancer care.

The fundamental principle of immunotherapy involves amplifying the body's immune response by introducing cells capable of recognizing and eliminating cancerous entities. By reactivating pre-existing immune cells and stimulating the formation of new immune responses, immunotherapy plays a crucial role in counteracting tumor progression. The effectiveness of these therapies relies on the coordinated involvement of diverse immune cell types, including antigen-presenting cells such as dendritic cells and macrophages, as well as T lymphocytes and natural killer cells. Each of these immune components contributes to orchestrating a targeted attack against tumors. However, cancer often induces both quantitative imbalances in immune cell populations and qualitative deficiencies in molecules and signaling pathways essential for modulating anti-tumor immunity. Therefore, the careful design and optimization of therapeutic strategies are essential for enhancing the efficacy of immunotherapy.

Depending on the type of cancer and its intrinsic mechanisms, multiple facets of the immune response offer promising avenues for therapeutic intervention. Various innovative approaches have been explored, including the extraction and expansion of immune cells that have previously recognized cancer cells, facilitating their reintegration into the patient's immune system.

Additionally, some methods focus on chemically inducing the differentiation of potent immune cell types. Beyond these conventional strategies, advanced techniques such as genetic engineering have led to the development of immune cells with enhanced tumor-recognition capabilities, including those modified with T cell receptors (TCRs) or chimeric antigen receptors (CARs), which have emerged as cutting-edge options in cancer immunotherapy.

In recent years, research into immune checkpoint inhibitors (ICBs) has revolutionized treatment strategies for highly aggressive breast cancer subtypes, particularly triple-negative breast cancer (TNBC). While ICBs such as pembrolizumab and atezolizumab have demonstrated remarkable efficacy in certain patient populations, many individuals with TNBC do not respond favorably to these treatments. This variation in response underscores the need for further investigation into the mechanisms underlying resistance to immune checkpoint blockade, which remains a critical barrier to optimizing patient outcomes.

Moreover, the challenge of targeting tumor heterogeneity represents another major obstacle in cancer immunotherapy. The unique characteristics of each tumor give rise to a vast array of potential neoantigens, complicating the development of vaccines that can effectively stimulate a strong and lasting immune response. Research efforts aimed at

identifying immunogenic neoantigens, validating their clinical relevance, and leveraging novel techniques such as single-cell sequencing and artificial intelligence for their identification stand at the forefront of the next wave of advancements in immunotherapy.

As the field continues to evolve, addressing these challenges through innovative research and personalized treatment strategies will be crucial in maximizing the potential of immunotherapy to improve outcomes for cancer patients worldwide.

Smoking as the Leading Cause of Lung Cancer

Smoking is the predominant cause of lung cancer, contributing to approximately 90% of all cases. Male smokers, in particular, are at the highest risk. The risk is further exacerbated when other environmental carcinogens, such as asbestos, are introduced. However, due to the complex interplay of genetic, environmental, and lifestyle factors, there is no simple correlation between the number of cigarettes smoked annually and lung cancer incidence.

Passive smoking is also a significant concern, as it increases the risk of lung cancer by 20–30%. Additionally, exposure to radiation therapy for malignancies unrelated to the lungs, such as breast cancer or non-Hodgkin's lymphoma, has been implicated in lung cancer development.

Furthermore, exposure to metals such as arsenic, nickel, and chromium, as well as polynuclear aromatic hydrocarbons, has been associated with an increased risk of lung cancer. Notably, even in the absence of smoking, individuals with idiopathic pulmonary fibrosis remain at risk for developing lung cancer.

Asbestos and Radon as Additional Risk Factors for Lung Cancer

Asbestos and radon exposure are also recognized as significant risk factors for lung cancer. Occupational exposure to asbestos increases lung cancer risk in a dose-dependent manner, with variations depending on the type of asbestos fiber. The health risks associated with non-occupational asbestos exposure remain a subject of debate, though regulatory guidelines have been established for limiting exposure to low or background levels. Generally, undisturbed asbestos poses minimal health risks, as airborne fibers are the primary hazard.

Regarding radon exposure, uranium miners face a small but notable increased risk of lung cancer. Radon, a naturally occurring radioactive gas, accumulates in buildings as a result of uranium and radium decay. A meta-analysis of European studies has indicated that residential radon exposure accounts for nearly 2% of all lung cancer deaths across the continent. Radon is particularly

hazardous for smokers, as its carcinogenic effects are significantly amplified when combined with tobacco smoke.

The Need for Innovative Preventive and Therapeutic Approaches, Including Vaccination

Given the increasing global burden of breast and lung cancers, there is a pressing need for groundbreaking preventive and therapeutic approaches, including vaccination strategies, to effectively combat these complex malignancies. Breast and lung cancers remain leading causes of cancer-related mortality worldwide, underscoring the necessity for innovative interventions beyond conventional therapies.

Recent advancements in cancer immunotherapy have demonstrated that therapeutic vaccines can stimulate the immune system to recognize and target tumor-specific antigens. Notably, mRNA-based vaccines have shown promise in both lung and breast cancers. Vaccines designed to target neoantigens and modulate immune checkpoint pathways have demonstrated potential in enhancing antitumor immune responses. Researchers have documented encouraging findings regarding the efficacy of these approaches in improving cancer treatment outcomes.

Preventive vaccines aimed at triple-negative breast cancer and lung cancer-specific antigens

are currently under investigation to reduce cancer risk in high-risk populations. Additionally, integrating vaccination strategies with established treatments, such as chemotherapy and radiotherapy, has the potential to enhance therapeutic efficacy and improve patient outcomes. These advancements highlight the transformative role that vaccination may play in the comprehensive management of lung and breast cancers. While promising, further research is necessary to fully establish the efficacy and long-term benefits of these innovative immunotherapeutic strategies.

Fundamentals of Cancer Vaccination

Definition of Therapeutic and Preventive Cancer Vaccines

Mechanisms of Cancer Vaccines, Such as Stimulating the Immune System to Recognize and Target Cancer Cells

Cancer Vaccination: A Notable Technological Advancement

The field of cancer vaccination has been rapidly expanding, representing a relatively new but promising area in oncology. This approach harnesses the patient's immune system to predict, identify, and combat cancerous diseases effectively. Cancer vaccines are classified into two main types based on their purpose: therapeutic vaccines, which are used for cancer treatment,

and preventive vaccines, which aim to reduce the likelihood of cancer development in healthy individuals who may be at risk.

Understanding Cancer Vaccines: Definition and Types

Clinical data from therapeutic cancer vaccines indicate that these vaccines function as immunotherapies designed to elicit a robust immune response against tumors through tumor antigens, which are categorized as either tumor-associated or tumor-specific antigens. These vaccines train the immune system to recognize and eliminate tumor cells, thereby reducing the risk of recurrence and metastasis.

Conversely, preventive cancer vaccines aim to induce immunity before oncogenesis occurs, particularly in individuals exposed to oncogenic viruses, specific risk factors, or pre-malignant lesions. A notable example is the prophylactic human papillomavirus (HPV) vaccine, which has been highly effective in preventing cervical, anal, and oropharyngeal cancers.

Mechanisms of Cancer Vaccines

Cancer immunotherapies function through multiple mechanisms that enhance immune responses. They stimulate both innate and adaptive immunity, leading to the activation of cancer antigen-presenting cells, primarily dendritic cells, which enable T cells to

recognize tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs). The subsequent activation of cytotoxic CD8+ T cells plays a crucial role in targeting and inducing apoptosis in cancer cells.

Most cancer vaccine formulations include adjuvants to enhance immune activation and counteract the immunosuppressive effects of the tumor microenvironment. Various therapeutic vaccine modalities are being developed, including peptide-based, DNA/RNA-based, dendritic cell-based, and viral vector-based vaccines. Peptide vaccines targeting TAA-expressing tumors have demonstrated effectiveness, particularly in melanoma and other cancers. Similarly, mRNA vaccines have shown promise in early clinical trials for lung and breast cancers due to their versatility and ability to generate rapid immune responses.

Preventive Cancer Vaccines and Viral Oncology

Cancer vaccines that target causative viral agents are often referred to as cancer-targeting virus vaccines. The hepatitis B virus (HBV) vaccine was among the first successful examples, significantly reducing the incidence of hepatocellular carcinoma in vaccinated individuals. Likewise, the development of HPV vaccines, such as Gardasil, has revolutionized cervical cancer prevention and has also been effective in preventing other HPV-

associated cancers.

Tumor Microenvironment and Immune Evasion

One of the major challenges in cancer vaccination is overcoming the immunosuppressive nature of the tumor microenvironment. Malignant cells can alter antigen expression and promote regulatory T (Treg) cell activity, which suppresses effector T cell responses. To address this issue, combination therapies, including immune checkpoint inhibitors, are being explored to enhance vaccine efficacy. These inhibitors can mitigate immune suppression, thereby improving the overall effectiveness of cancer vaccines.

Challenges and Limitations

Despite promising advancements, several challenges persist in cancer vaccine development. Identifying and selecting appropriate tumor target antigens remains a critical hurdle, as tumors can induce immune tolerance or suppression. Additionally, achieving long-term immune memory to prevent relapse remains a significant barrier. The development of vaccines capable of inducing durable immune responses is a key focus of ongoing research.

Integration with Other Therapies

There is substantial evidence suggesting that combining cancer vaccines with established

therapeutic approaches, such as chemotherapy and radiotherapy, enhances antitumor immune responses. Immunomodulatory agents, including interleukin-2 and granulocyte-macrophage colony-stimulating factors, have been shown to further amplify the immune activation induced by vaccines. These combination strategies hold great promise in improving treatment outcomes.

Targeted Cancer Vaccines

Advancements in genomics and bioinformatics have led to the development of personalized cancer vaccines. These custom-designed vaccines target unique neoantigens that arise from a patient's specific tumor mutational landscape. Personalized cancer vaccines have shown significant promise in clinical trials, particularly in the treatment of melanoma and glioblastoma. Such individualized approaches represent a significant step toward precision medicine in oncology.

Future Perspectives on Cancer Vaccination

The future of cancer vaccination lies in the development of novel vaccine formulations and combinatorial therapeutic approaches. Emerging trends in nanotechnology and immunogenomics are expected to play a pivotal role in overcoming existing challenges. By integrating these cutting-edge technologies, researchers aim to enhance

vaccine efficacy, optimize immune responses, and improve long-term clinical outcomes. Cancer vaccines are poised to become a transformative tool in the fight against cancer, offering new hope for prevention and treatment.

Advancements in Vaccination for Breast Cancer

Overview of Vaccines Under Development for Breast Cancer

Key Findings from Recent Clinical Studies, Including the Phase I Trial of HER2 Vaccines Demonstrating Safety and Tolerability

Advancements in Vaccination for Breast Cancer

Breast cancer is the second most commonly diagnosed cancer worldwide, contributing significantly to morbidity and mortality. This widespread prevalence underscores the need for continuous research, investment, and development in the field. One promising area of cancer immunotherapy is the targeted development of vaccines against tumor-specific antigens. Among these, HER2 has emerged as a crucial immunotherapeutic target, as it is overexpressed in approximately 15–20% of all breast cancer cases. The purpose of HER2-antibody-expressing vaccines is to effectively eliminate HER2-positive breast cancer cells while minimizing harm to healthy tissues.

Breast cancer is the most common malignancy in women, with approximately 2.3 million new

cases diagnosed annually. By 2020, breast cancer had surpassed lung cancer as the most frequently diagnosed cancer and became the leading cause of cancer-related mortality among women worldwide.

Breast cancer vaccines typically comprise antigens, delivery systems, and adjuvants. The targeted antigens are proteins or molecules that are either overexpressed or abnormally expressed in breast cancer cells, making them optimal candidates for triggering an immune response. Commonly targeted antigens include HER2/neu, MUC-1, and NY-ESO-1, all of which are overexpressed in various breast cancer subtypes. These antigens are essential for cancer cell survival and proliferation, making them promising targets for immunotherapy.

The selection of an antigen is crucial, as it determines the vaccine's ability to elicit a strong immune response. While tumor-associated antigens (TAAs) such as HER2/neu are widely utilized, there is increasing interest in targeting mutated proteins and neoantigens. These molecules arise from somatic mutations specific to the tumor and are absent in normal tissues, making them especially promising for personalized immunotherapy. Although less common, mutated proteins and neoantigens are particularly valuable targets in triple-negative breast cancer.

Various vaccine platforms, including DNA-based,

dendritic cell-based, and peptide-based vaccines, have been the focus of multiple clinical trials. While these platforms have demonstrated potential in preclinical studies, clinical trials have yet to achieve significant endpoints in terms of overall survival or tumor regression.

Despite promising developments, the complexity of the immune system and the heterogeneity of breast cancer present significant challenges. Tumor-induced immunosuppression and immune evasion remain major obstacles that must be addressed to optimize the efficacy of breast cancer vaccines.

The World Health Organization has identified cancer as the second leading cause of death worldwide. The burden of this disease is high, and the probability of survival remains low.

Among cancers affecting women, breast cancer (BC) accounts for 25% of cases, making it the most common cancer in women. However, less than 1% of cases also occur in men. This disease has a high incidence and ranks as the fifth leading cause of cancer-related mortality among women.

The risk factors for breast cancer include family history, an unhealthy lifestyle, and poor dietary habits. However, despite extensive research, the understanding of its physiopathology remains insufficient. The BRCA1 and BRCA2 genes play a critical role in repairing DNA damage and maintaining genomic stability. Mutations in these genes are responsible for hereditary breast cancer

in 40% to 85% of cases, significantly increasing the risk of disease development.

Breast cancer can manifest in invasive and non-invasive forms, with metastasis occurring in 5% to 10% of cases. Therefore, prevention, early diagnosis, and appropriate treatment are crucial for improving patient prognosis, as determining a reliable prognosis remains a challenge. Immune-based treatments have emerged as a promising approach to reducing cancer morbidity and mortality.

One of the novel strategies in cancer treatment is immunotherapy, with cancer vaccines being a key component of this approach. Therapeutic cancer vaccines aim to stimulate an adaptive immune response against tumor antigens, leading to tumor regression. However, resistance mechanisms present a major challenge in this type of treatment. Compared to other therapies, vaccines hold significant potential in managing BC, particularly in cases of relapse and drug resistance.

Cancer immunotherapy vaccines are classified into two main types: prophylactic and therapeutic vaccines. Combining cancer vaccines with immunotherapy may enhance treatment outcomes, as such combinations target multiple components of the immune system and the tumor microenvironment (TME) simultaneously. This dual approach helps shift the balance between immune activation and suppression, improving

therapeutic efficacy.

The primary objective of cancer vaccination is to stimulate the immune system to recognize and eliminate tumor-associated antigens (TAA) or tumor-specific antigens (TSA). The design of effective cancer vaccines should prioritize highly immunogenic antigens, as their recognition enables the immune system to develop long-lasting immunity and prevent disease relapse.

The immunoediting hypothesis describes the immune system's dynamic interaction with tumor cells through three phases: elimination, equilibrium, and escape. Tumor cells that evade immune detection enter the escape phase, resulting in tumor progression. Active immunotherapy provides a protective effect against tumors by modifying the immune microenvironment and restoring anti-tumor surveillance. Neoantigen-driven therapeutic cancer vaccines are a major focus of active immunotherapy, with their combination with immune checkpoint inhibitors (ICIs) showing clinical benefits across multiple cancer types.

Immunotherapy vaccines utilize the patient's immune system to recognize and destroy cancerous cells. Cancer cells release chemokines, cytokines, and prostaglandins that recruit various immune cells, such as macrophages, neutrophils, and lymphocytes. These immune cells subsequently activate tumor necrosis factor (TNF), interferons (IFN), matrix

metalloproteinases, natural killer (NK) cells, and T cells, contributing to cancer cell destruction.

Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in improving survival rates for several cancers, including gastric cancer, lung cancer, and melanoma. However, their use in breast cancer remains largely limited to first-line and neoadjuvant therapy for triple-negative breast cancer (TNBC).

The tumor microenvironment (TME) plays a crucial role in cancer detection, prevention, and early eradication. However, in BC, the TME often acts as a major barrier to effective treatment. Breast cancer frequently recruits immune cells that, rather than attacking the tumor, create an immunosuppressive microenvironment, thereby fostering tumor growth by inhibiting immune activity.

Additionally, several challenges hinder the development of breast cancer vaccines, including the selection of TAAs as therapeutic targets, the stage of cancer, and the inherently low immunogenicity of vaccines. The latter may result from the choice of antigen or the delivery platform used in vaccine formulation, affecting its overall effectiveness.

Breast cancer is classified into three main subgroups based on the presence or absence of human epidermal growth factor receptor 2 (HER2), progesterone receptor (PR), and estrogen receptor (ER). The role of vaccines in breast cancer

treatment holds promise, as it is based on the hypothesis that B or T cell-mediated immune responses can effectively eliminate cancer cells.

Various breast cancer vaccines under investigation utilize different approaches, including DNA-based, peptide-based, carbohydrate-based, and tumor cell antigen-based vaccines. Among these, peptide-based vaccines have garnered significant attention in clinical research. By targeting breast cancer antigens, peptide-based vaccines present a viable alternative to conventional treatments.

Despite the well-established safety and long-term protection offered by vaccines, the U.S. Food and Drug Administration (FDA) has not yet approved any breast cancer vaccine for treatment or prevention. Several vaccines are currently being studied in TNBC patients to prevent relapse or serve as a treatment option, but none have received regulatory approval.

A review of multiple clinical trials indicates that vaccines are generally safe and capable of inducing cellular immune responses. However, most studies have failed to demonstrate significant improvement in clinical efficacy metrics. One potential reason for these negative results is the limited duration of vaccine-induced anti-tumor immunity, which may not be sufficient to achieve meaningful survival benefits. The early decline in immune response could be attributed to an immunosuppressive tumor microenvironment,

suboptimal vaccine formulations, or immune tolerance to specific tumor antigens.

Despite the implementation of various strategies, the development of an effective cancer vaccine remains a challenge due to inadequate immunogenicity, difficulties in antigen identification, tumor heterogeneity, and other complexities. Continued research and advancements in immunotherapy are essential to overcoming these barriers and achieving effective vaccine-based treatments for breast cancer.

Overview of Vaccines Under Development for Breast Cancer

Currently, HER2-targeted vaccines are being developed in multiple formats, including peptide-based, DNA-based, and dendritic cell-based vaccines. Peptide vaccines, such as E75 (nelipepimut-S), enhance cytotoxic T lymphocyte (CTL) recognition and destruction of HER2-expressing cells. DNA-based vaccines function by encoding HER2 epitopes within the body, thereby stimulating greater immune activation through genetic platforms. Dendritic cell vaccines, which utilize HER2 peptides, work by directly presenting tumor antigens to T cells, triggering an effective anti-tumor immune response.

Phase I Clinical Trials of HER2 Vaccines

Clinical trials investigating HER2 vaccines have

reported promising results in terms of safety and therapeutic benefits. A notable Phase I trial of a HER2 DNA vaccine demonstrated encouraging outcomes, with no significant adverse events observed and a majority of HER2-positive breast cancer patients exhibiting strong immune responses to the vaccine. Similarly, studies on E75 and other peptide-based HER2 vaccines in combination with adjuvants found that these vaccines were safe and contributed to a reduction in recurrence rates among early-stage breast cancer patients.

Immune Mechanisms of HER2 Vaccine Action

HER2-targeted vaccines function by activating the adaptive immune system, particularly CD8+ cytotoxic T cells and CD4+ helper T cells, which recognize HER2 antigens on tumor cells. This immune activation leads to the targeted destruction of HER2-positive cancer cells while sparing normal tissues. Additionally, these vaccines promote the generation of memory T cells, which play a crucial role in long-term protection against tumor recurrence.

Combination Therapies to Enhance Vaccine Efficacy

To further enhance the efficacy of HER2 vaccines, they can be combined with immune checkpoint inhibitors or monoclonal antibody

therapeutics, such as Trastuzumab. Immune checkpoint inhibitors, including anti-PD-1 and anti-CTLA-4 antibodies, work by counteracting tumor-induced immunosuppression, allowing vaccine-activated T cells to maintain their anti-tumor function. Meanwhile, monoclonal antibodies like Trastuzumab target HER2 directly, increasing antigen presentation and promoting antibody-dependent cellular cytotoxicity, thereby strengthening the overall immune response.

Challenges in HER2 Vaccine Development

Despite encouraging progress, several challenges persist in the development of HER2-targeted vaccines. One major issue is the need to define the patient populations that would benefit most from therapy, as HER2 expression varies significantly across different breast cancer subtypes. Additionally, overcoming immune tolerance toward HER2, which is a self-antigen, remains a critical challenge. Strategies such as combination therapies, optimization of adjuvants, and other immunomodulatory approaches are being explored to address these obstacles.

Advancements in mRNA-Based HER2 Vaccines

Recent advancements in mRNA vaccine technology have opened new possibilities for HER2-targeted breast cancer vaccines. mRNA

vaccines are highly customizable and can be engineered to elicit immune responses against specific HER2 epitopes. Early preclinical studies have shown promising results, demonstrating effective T-cell activation and significant tumor inhibition in initial phases of therapy.

Individualization of HER2 Vaccines

A growing area of research focuses on developing personalized HER2 vaccines tailored to individual tumors. These vaccines target patient-specific HER2 mutations or neoantigens, which could improve efficacy while minimizing off-target effects. Advances in genomics and bioinformatics are facilitating the identification of individualized epitopes, enabling the formulation of personalized cancer vaccines designed to optimize treatment outcomes.

Prospective Horizons in HER2 Vaccine Development Research

Future research aims to further improve HER2 vaccine efficacy by integrating advanced delivery platforms, such as nanoparticle-based formulations, which enhance antigen stability and immune activation. Additionally, the combination of HER2 vaccines with innovative immunomodulators is being investigated to maximize therapeutic effects and improve long-term patient outcomes.

The Advantages of HER2-Targeted Vaccines from a Breast Cancer Perspective

HER2-targeted vaccines represent a significant advancement in breast cancer treatment. Several clinical trials have demonstrated improvements in safety and efficacy, reinforcing the potential of these vaccines as part of multimodal treatment strategies. While challenges remain, the integration of HER2 vaccines into combination therapies, along with emerging mRNA-based vaccine approaches, holds great promise for improving survival rates and quality of life for patients with HER2-positive breast cancer.

Active and Passive Vaccination of Breast Cancer

Active Vaccination

Active vaccination refers to the use of specific tumor-associated antigens (TAAs) to trigger an immune response. Peptide-based vaccines have advantages such as ease of generation, cost-effectiveness, and efficient immune response evaluation, but they also have certain limitations. Peptide vaccines targeting MAGE-A3 and NY-ESO-1, which are preferentially expressed in TNBC, represent a promising field of study. Additionally, the HER2 peptide E75 (aa 369–377) vaccine, also known as nelipepimut-S, has

been evaluated in a phase I/II trial involving 195 women with early-stage HER2-positive breast cancer. Results showed a five-year disease-free survival (DFS) rate of 89.7% in the vaccinated group compared to 80.2% in the control group. Patients who received a booster injection (n=53) showed an even higher five-year DFS rate of 95.2%. Another HER2-directed vaccine, GP2, derived from the transmembrane domain of HER2 (aa 654–662), has been studied in a phase II trial (n=170), demonstrating an increased DFS in vaccinated patients.

Mucin 1 (MUC-1), which is frequently overexpressed in cancer cells, plays a role in increasing tumor cell proliferation and metastasis. Anti-MUC-1-derived vaccines have shown promise, with studies demonstrating that these vaccines elicit strong cytotoxic and humoral responses while significantly reducing recurrence rates.

Dendritic cells (DCs) are among the most potent antigen-presenting cells, playing a critical role in T cell activation. In a study by Sharma et al., the HER2 DC vaccine was administered to 27 patients with HER2-overexpressing ductal carcinoma in situ (DCIS) before surgical resection. Results showed a complete pathological response in 18.5% of patients, indicating no evidence of DCIS.

Passive Vaccination

Passive vaccination involves the transfer of active humoral immunity. Antibodies such as pertuzumab and trastuzumab are currently prescribed for HER2-positive breast cancer. However, these antibodies have limitations, including high costs, inadequate efficacy, and treatment resistance.

Cyclin-dependent kinases (CDKs), particularly CDK4 and CDK6, play crucial roles in cell cycle regulation. Several CDK inhibitors, including abemaciclib, palbociclib, and ribociclib, are currently under clinical investigation. Additionally, immune checkpoint inhibitors such as atezolizumab and pembrolizumab have shown efficacy in TNBC, enhancing tumor-specific responses and blocking immunosuppressive pathways.

Advancements in Vaccination for Lung Cancer

Introduction to mRNA-Based Vaccines for Lung Cancer, Such as BioNTech's BNT116 Vaccine

Preliminary Results from Clinical Trials Showing Promising Immune Responses and Safety Profiles

Developments in Cancer Vaccination – Lung Cancer

Lung cancer remains the leading cause of cancer-related mortality worldwide, accounting for nearly 18% of all cancer deaths. Unfortunately, the prognosis for lung cancer patients,

particularly those in advanced stages, remains poor despite advances in targeted therapies and immunotherapy. Novel vaccination approaches, including the application of mRNA technologies, offer promising potential to enhance treatment responses in lung cancer patients.

Lung cancer is the second most frequently diagnosed malignancy and the leading cause of cancer-related mortality worldwide. Histologically, lung cancers are categorized into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for approximately 85% of cases and is further divided into four subtypes: adenocarcinoma, large cell carcinoma, squamous cell carcinoma, and bronchial carcinoid tumor, with adenocarcinoma being the most common.

The tumor microenvironment (TME) plays an essential role in cancer development, progression, and response to treatment. Immune cells are crucial in shaping the TME, and the dynamic relationship between these cells and the TME significantly impacts tumor behavior. The lung TME consists of various cells, including macrophages, dendritic cells (DCs), natural killer (NK) cells, T cells, B cells, neutrophils, fibroblasts, mesenchymal cells, stromal cells, soluble mediators, and the extracellular matrix. Lung cancer often disrupts the balance between immune activation and suppression, promoting immune suppression and enabling

tumor progression. For example, an increase in immunosuppressive CD4+ CD25+ regulatory T cells has been observed in NSCLC tumors, while higher levels of CD8+ T cells have been linked to favorable prognoses in these patients. Several NSCLC studies have highlighted that an overall increase in tumor-infiltrating lymphocytes correlates with improved survival rates and reduced systemic recurrence. Accordingly, vaccine strategies for lung cancer aim to restore immune activation to counteract suppression and enhance anti-tumor responses.

Unlike conventional vaccines, which are designed to prevent infections, cancer vaccines are administered either to prevent tumor formation (prophylactic) or as part of cancer treatment (therapeutic). Recent advancements in therapeutic cancer vaccines have led to novel delivery systems and tumor-specific antigens. The development of lung cancer vaccines has resulted in four main categories: peptide/protein-based, cell-based, gene-based, and virus-based vaccines.

Lung cancer (LC) is one of the most common cancers worldwide and has a high mortality rate. It is the leading cause of cancer-related deaths globally. The risk factors for LC include smoking, prolonged exposure to polluted air—especially polycyclic aromatic hydrocarbons, asbestos, and radon—as well as a personal or familial history of the disease.

Lung cancer is histologically classified into two

types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC being the most prevalent form, accounting for 85% to 90% of cases.

Most conventional chemotherapy drugs have significant limitations in their efficacy, such as non-specific targeting, low bioavailability, and the development of drug resistance. Despite recent advancements in lung cancer treatments, the overall survival rate remains low, at less than 15%. This highlights the need for further research into preventive and therapeutic strategies, including vaccines.

Immunotherapy is an innovative approach in lung cancer treatment and includes various strategies such as cancer vaccines, immune checkpoint inhibitors (ICIs), and cellular immunotherapies. These treatments aim to strengthen or initiate immune responses against tumors. Immunotherapy has been shown to improve patient survival, reduce side effects, and enhance quality of life.

Therapeutic cancer vaccines are particularly promising in improving antitumor responses, especially in patients who exhibit poor responses to ICIs. Cancer vaccines based on off-the-shelf allogeneic dendritic cells (DC), such as PDC*vac, in combination with ICIs, offer a promising avenue for innovative treatments. These vaccines circumvent the challenges associated with using autologous products and are currently under

investigation for lung cancer therapy.

Some ICIs have replaced chemotherapy drugs and are now widely used in combination with other treatments for lung cancer and various other malignancies. ICIs enhance the body's immune response by increasing the activity of antitumor and cytotoxic CD8+ T cells (ASTCs).

Microparticles (MPs), also known as microvesicles, are released from cell surface membranes into the extracellular environment. In the lung cancer microenvironment, MPs are present in normal and cancerous cells, as well as in tumor-infiltrating immune cells. MPs facilitate intercellular communication, making tumor-derived MPs (TMPs) a viable option for delivering therapeutic agents to tumor cells. Their ability to carry large amounts of biological information makes them an effective tool in the development of novel cancer vaccines.

A personalized tumor neoantigen-based vaccine formulation, FRAME-001, has demonstrated efficacy in treating stage III-IV NSCLC. Therapeutic cancer vaccines, which specifically activate the immune system, have the potential to enhance anti-tumor immune responses significantly.

Mutated neoantigens in cancer cells possess a strong capacity to induce immune responses against tumors. They serve as primary targets for T cell-mediated immunity and have been extensively studied in the development of personalized cancer vaccines.

MVA-based vaccines, when combined with anti-PD-1/PD-L1 immunotherapy, present a promising option for the personalized treatment of NSCLC. A nanovaccine containing tumor cells has been shown to activate CD8+ and CD4+ T cells, subsequently inducing tumor-specific immune responses that aid in the identification and elimination of cancerous cells.

Combining therapeutic cancer vaccines with ICIs has yielded improved treatment outcomes. Vaccine-based therapies are particularly suitable for SCLC patients, especially those who have recently completed chemotherapy, due to their potential for minimal toxicity. Some trials have reported a 40% increase in survival rates with this approach. Additionally, these vaccines are being used in combination with other drugs by ImClone Systems in the United States and Merck Oncology in Europe, Australia, and New Zealand.

Four other antigens—Globo H, GM2, polysialic acid, and fucosyl GM1—have been identified as potential targets for immunotherapy in SCLC. Although some immune responses have been observed in patients following antigen administration, further testing is required to establish their clinical efficacy.

p53 is another target antigen currently being investigated in the treatment of SCLC. Studies suggest that vaccines targeting p53 elicit strong immune responses when combined with chemotherapy. However, vaccine therapy

alone may not be sufficient, and sequential chemotherapy may be necessary to achieve optimal treatment outcomes.

Personalized peptide vaccines (PPVs) have also shown potential in prolonging overall survival (OS) and rejuvenating the immune system, yet they require further evaluation to confirm their effectiveness.

Immunotherapy has revolutionized lung cancer treatment by shifting the treatment paradigm away from traditional chemotherapy. ICIs have significantly improved OS while causing fewer adverse effects than chemotherapy. Various types of vaccines are currently undergoing clinical trials, demonstrating promising results. However, further research is essential to validate their efficacy and integrate them into routine clinical practice.

Dendritic Cell Vaccines

Effective interactions between T cells and DCs are crucial for eliciting a robust anti-tumor immune response. Researchers suggest that targeting tumor antigens alone may not trigger a strong enough immune response to be therapeutically effective. DCs function as professional antigen-presenting cells that activate CD8+ and CD4+ T cells by presenting antigens via MHCI and MHCII molecules, making them ideal candidates for vaccine development in NSCLC. In addition to priming T cells to recognize tumor antigens,

DCs enhance interactions with other immune cells within the TME, thereby amplifying anti-tumor immunity. Clinical trials of monotherapy with DC vaccines in NSCLC have demonstrated significant immune responses, such as increased IFN-γ secretion from circulating patient-derived lymphocytes, but a direct correlation with improved survival has seldom been observed.

Protein-Based Vaccines

Antigen-specific immunotherapy introduces tumor-associated antigens along with immunostimulants to provoke a strong anti-tumor response. One promising target is melanoma-associated antigen (MAGE)-A3, which is aberrantly expressed in cancer cells but absent in normal tissues except for germline and placental cells. MAGE-A3 is expressed in 35% of NSCLC cases, with its expression increasing as the disease progresses—30% of stage I patients and 50% of stage II patients express MAGE-A3 in their primary tumors. Consequently, MAGE-A3 expression is indicative of poor prognosis.

Clinical trials have demonstrated that MAGE-A3 vaccines are well-tolerated and exhibit clinical benefits, particularly in patients with specific gene signatures. Similarly, in preclinical models, a peptide vaccine conjugated with CpG has shown enhanced immune cell infiltration into the lungs following intranasal administration.

Epidermal Growth Factor (EGF)-Based Vaccine

Numerous epithelial malignancies, including lung cancers, exhibit overexpression of epidermal growth factor (EGF) and its receptor (EGFR). Over the past decade, multiple small molecule inhibitors targeting EGFR-related tyrosine kinases and monoclonal antibodies against EGFR have been developed. A vaccine consisting of human recombinant EGF conjugated to the carrier protein P64K was evaluated in three pilot clinical trials, followed by a pooled analysis of 83 patients with stage IIIB/IV NSCLC. The vaccine elicited specific anti-EGF antibody titers in 83% of participants, with 49% exhibiting a robust anti-EGF antibody response. A correlation between strong antibody responses and improved survival was observed consistently across all trials, regardless of differences in study design. Additionally, a phase II clinical trial of a human recombinant EGF-based vaccine was conducted in patients with advanced NSCLC who had completed chemotherapy. The results demonstrated safety, increased anti-EGF antibody levels, and reduced serum EGF levels, with a positive correlation between antibody response and overall survival.

Allogeneic Tumor Cell Vaccines

Transforming growth factor-beta (TGF-β) plays an immunosuppressive role in various tumors,

including lung cancer, by inhibiting both NK cells and dendritic cells (DCs), making it a recognized poor prognostic factor. Belagenpumatucel-L, a vaccine composed of four allogeneic genetically modified NSCLC cell lines, was designed to secrete an antisense oligonucleotide targeting TGF-β2. A study by Nemunaitis et al. evaluated the efficacy and safety of belagenpumatucel-L in 75 patients with stage II to IV NSCLC. While the study did not include a control group receiving chemotherapy alone, advanced-stage patients who received a high dose of the vaccine exhibited an estimated two-year survival rate of 47%, compared to 18% in the lower-dose group.

These findings suggest the possibility of managing advanced cancer as a chronic disease through low-toxicity therapeutic approaches. Several lung cancer vaccination strategies are currently under investigation, with variations in administration routes, carriers, adjuvants, and combination therapies influencing their outcomes. Despite ongoing challenges, lung cancer vaccines remain an active area of research. Phase III trials of vaccines such as L-BLP25, MAGE-A3, and belagenpumatucel-L have demonstrated potential benefits, emphasizing the importance of integrating vaccines with chemotherapy and radiation in multimodal treatment strategies.

An Overview of mRNA Vaccines

for the Treatment of Lung Cancer

Cancer immunotherapy has undergone a paradigm shift with the introduction of mRNA-based vaccines, which can induce potent immune responses with high specificity. These vaccines have also proven to be flexible in design and rapid in development. A notable example is BioNTech's BNT116 vaccine, which is designed for patients with advanced non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer. BNT116 works by encoding tumor-associated proteins specific to NSCLC, allowing the immune system to recognize and eliminate tumor cells more effectively.

Mechanism of Action of mRNA Vaccines for the Treatment of Lung Cancer

mRNA vaccines function by introducing synthetic messenger RNA (mRNA) into host cells, which then use the mRNA to produce tumor-associated antigens. These antigens are subsequently recognized by antigen-presenting cells (APCs), such as dendritic cells, which activate CD8+ cytotoxic T cells and CD4+ helper T cells. This immune activation enables the destruction of cancer cells expressing the targeted antigens, thereby enhancing the body's ability to fight lung cancer.

Clinical Trials of BNT116:

Progress and Preliminary Results

Early-phase clinical trials of BNT116 have yielded promising results. A Phase I trial involving patients with advanced NSCLC demonstrated a favorable safety profile, with mild to moderate side effects, such as fever and fatigue. Immunological assays confirmed robust activation of T cells specific to the encoded antigens, with most participants exhibiting sustained immune responses. These preliminary findings suggest that BNT116 has the potential to significantly improve treatment outcomes for NSCLC patients.

Combining mRNA Vaccines with Checkpoint Inhibitors

The efficacy of mRNA vaccines, such as BNT116, may be further enhanced when combined with immune checkpoint inhibitors, such as anti-PD-1 or anti-PD-L1 therapies. Checkpoint inhibitors help to counteract the immunosuppressive tumor microenvironment, allowing vaccine-activated T cells to maintain their anti-tumor activity. There is emerging evidence that patients receiving both BNT116 and checkpoint inhibitors experience better clinical outcomes compared to those receiving checkpoint inhibitors alone.

Personalized mRNA Cancer Vaccines

One of the most appealing features of mRNA

vaccines is their adaptability to individual patients. Since tumors exhibit unique genetic mutations, personalized mRNA vaccines can be designed to target patient-specific neoantigens —genetic variants present only in a particular patient's tumor. This personalized approach enhances immune specificity and strengthens the overall immune response, potentially improving treatment effectiveness.

Safety and Tolerability of mRNA Vaccines

Ensuring safety is a fundamental aspect of vaccine development. Early-phase studies of BNT116 have demonstrated excellent tolerability, with adverse effects being mild and self-limiting. Unlike traditional vaccines, mRNA-based vaccines do not integrate into the host genome, reducing the risk of genetic alterations and further enhancing their safety profile.

Challenges and Strategies for Lung Cancer Vaccination

Lung cancer presents unique challenges for vaccination due to its immunosuppressive tumor microenvironment and high mutational burden. Efforts to improve vaccine efficacy include the co-administration of mRNA vaccines with adjuvants that enhance APC activation. Additionally, advanced delivery mechanisms, such as lipid nanoparticles, are being employed to improve

mRNA stability and localization at target sites, thereby optimizing the immune response.

Future Directions in mRNA Cancer Vaccines for Lung Cancer

The future of mRNA vaccines for lung cancer will focus on refining vaccine design and delivery methods. Emerging strategies include leveraging nanotechnology-based platforms and advanced bioinformatics tools to enhance antigen targeting and optimize immune activation. Furthermore, large-scale clinical studies will be essential to assess the effectiveness of BNT116 across diverse patient populations and to explore its potential as part of combination therapy regimens.

Conclusion

The development of mRNA vaccines has ushered in a new era in cancer treatment, with BioNTech's BNT116 emerging as a promising candidate for lung cancer therapy. Clinical trials have demonstrated its safety and efficacy, with encouraging immune responses observed in patients. While challenges remain, ongoing research and the integration of mRNA vaccines with other therapeutic modalities hold significant promise for improving lung cancer treatment and patient outcomes in the future.

Challenges in Cancer Vaccine Development

Scientific Hurdles, Including Tumor Heterogeneity and Immune Evasion Mechanisms

Clinical Challenges, Such as the Need for Extensive and Long-Term Trials to Establish Efficacy

Challenges in Cancer Vaccine Development

The concept of developing cancer vaccines that harness the immune system to recognize and eradicate tumors has gained significant attention in recent years. However, progress in this field remains insufficient, as there are considerable scientific and clinical challenges to overcome. Addressing these hurdles is essential to maximize the potential benefits of cancer vaccines for both preventive and therapeutic management across various cancer types.

Scientific Hurdles in Cancer Vaccine Development

Tumor Heterogeneity

One of the major challenges in cancer vaccine development is tumor heterogeneity, which encompasses genetic variations within tumor populations. These variations exist not only between patients but also within the tumor bulk of an individual patient over time. This heterogeneity complicates the identification of universal tumor antigens, as only a fraction of tumor cells harbor the mutations responsible for

generating neoantigens.

Immune Evasion Mechanisms

Tumors have evolved sophisticated mechanisms to evade immune detection. These include the downregulation of major histocompatibility complex (MHC) molecules and the release of immunosuppressive cytokines such as TGF-β and IL-10. These strategies block T-cell activation and impair immune responses, thereby limiting the effectiveness of cancer vaccines. Additionally, tumors can recruit regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) to further suppress immune function and facilitate immune escape.

Target Antigen Selection

Effective cancer vaccination requires the identification of suitable tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs). However, many TAAs are self-antigens, which raises concerns about the potential for autoimmune responses. Neoantigens, arising from tumor-specific mutations, represent a promising alternative, but their inherent variability and patient-specific differences present additional complications in their use for vaccine development.

Tumor Microenvironment

The immunosuppressive tumor

microenvironment (TME) presents a fundamental barrier to the efficacy of cancer vaccines. A characteristic feature of the TME is hypoxia, which not only inhibits the activity of cytotoxic T lymphocytes (CTLs) but also promotes cancer cell survival. Overcoming the challenges posed by the TME will require innovative vaccine strategies that incorporate other therapeutic modalities, such as immune checkpoint inhibitors, to enhance immune response and vaccine efficacy.

Clinical Challenges in Cancer Vaccine Development

Long-Term Effectiveness

One of the most significant clinical challenges in cancer vaccine development is demonstrating long-term efficacy. Unlike vaccines for infectious diseases, such as those for polio or measles, which typically require only a single dose to confer immunity, cancer vaccines often need to be administered multiple times over an extended period. Long-term trials are essential to assess the chances of tumor recurrence and overall survival, which are key indicators of the vaccine's success.

Multi-Center, Multi-Phase Clinical Development

The development of cancer vaccines necessitates large, multi-center clinical trials, often involving Phase II or Phase III studies. These trials are both

time-consuming and expensive. Additionally, the inter-individual variability in responses—due to differences in tumor types, genetic makeup, and prior treatments—adds complexity to the development process.

Patient Recruitment

Recruiting appropriate patient populations for clinical trials is another major challenge. Ideally, patients with minimal residual disease, just after cancer diagnosis, would benefit most from vaccination. However, many clinical trials involve patients with advanced or refractory cancers, whose tumors have already established a robust immunosuppressive TME, which may impair vaccine efficacy.

Regulatory and Manufacturing Issues

Obtaining regulatory approval for cancer vaccines is a challenging process that requires substantial evidence of safety, efficacy, and quality control. For personalized neoantigen vaccines, which are tailored to individual patients, good manufacturing practice (GMP)-compliant production processes are essential but complex. These manufacturing hurdles add to the overall cost and timeline of vaccine development.

Immune-Related Adverse Events (irAEs)

While cancer vaccines are generally well tolerated, they can induce immune-related adverse events (irAEs) due to immune system stimulation. These events can include vasculitis, autoimmune reactions, and other inflammatory responses. Managing and monitoring these adverse effects is crucial to ensure patient safety and maintain the acceptability of cancer vaccines as a treatment option.

Strategies to Overcome Challenges

Researchers are exploring several strategies to overcome the challenges associated with cancer vaccine development. The combination of cancer vaccines with immune checkpoint inhibitors has shown promise in reversing immune suppression and enhancing T-cell responses. The rapid advancements in genomics and bioinformatics technologies now allow for the identification of personalized neoantigens, which can enhance the specificity and effectiveness of cancer vaccines. Additionally, novel vaccine delivery systems, such as nanoparticles and viral vectors, have been developed to improve the stability and efficiency of antigen delivery.

Conclusion

The development of cancer vaccines is fraught with scientific and clinical challenges, from addressing the cellular diversity of tumors

and their immune escape mechanisms to the need for long-term clinical trials. However, these barriers can be overcome through the application of new strategies, such as combining vaccines with other therapeutic approaches and embracing personalized medicine. While the road to successful cancer vaccines is complex, the field holds great promise, with the potential to significantly improve the quality of life for cancer patients and even non-cancer patients through enhanced immune health.

Role of Artificial Intelligence in Cancer Vaccine Development

Use of AI in Identifying Suitable Antigens for Vaccine Design

Application of Machine Learning Algorithms to Predict Immune Responses and Optimize Vaccine Formulations

Role of Artificial Intelligence in Cancer Vaccine Development

Artificial intelligence (AI) is truly revolutionizing the field of cancer immunotherapy and vaccine development. AI is further augmented by advanced technologies such as machine learning (ML) and deep learning (DL), which significantly contribute to overcoming challenges like antigen mapping, prediction of immune responses, and optimization of vaccine formulations. AI expedites cancer vaccine development by processing vast amounts of data, allowing for

faster and more accurate production of these vaccines.

The Approach of AI in Identifying Effective Antigens for Vaccine Development

Antigen Discovery Through Artificial Intelligence

A crucial step in developing cancer vaccines is identifying tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs). AI algorithms analyze patterns in genomic, transcriptomic, and proteomic data to identify antigens that are overexpressed in tumor cells but absent in normal cells. Deep learning algorithms, in particular, have been developed to identify mutant pseudo-antigens. These neoantigens possess characteristics that are more closely associated with cancer cells and provoke fewer autoimmune responses, making them ideal candidates for vaccines.

Antigen Epitope Prediction and Preparation

Artificial intelligence also enhances the accuracy and efficiency of predicting antigen presentation through major histocompatibility complex (MHC), an essential process in triggering an immune response. Neural networks, such as NetMHC or NetMHCpan, utilize AI to predict peptide-MHC

binding and specificity, thereby improving the effectiveness of cancer vaccines.

AI for Validation and Integration of Potential Antigens Using Multi-Omics

Once potential antigens that could induce immune responses are identified, AI combines multiple omics datasets—such as genomic, transcriptomic, and epigenomic information—to optimize the process. This integration of data helps define antigen immunogenicity, enhancing the efficiency of antigen selection for vaccine development.

Machine Learning Algorithms for Modeling Immune Responses and Optimizing Vaccine Formulations

Prediction of Immune Response

AI's application extends to immune modeling, particularly in the context of cancer vaccines. Machine learning (ML) can be used to analyze longitudinal datasets, such as patient immune profiles, to identify potential immune responses. For instance, a model developed by Dhainaut et al. predicts T-cell activation based on the characteristics of the antigen and the system used to deliver the vaccine.

Optimization of Vaccine Formulations

Machine learning also aids in selecting the optimal combination of antigens, adjuvants, and delivery systems for specific vaccine formulations. For example, AI has been employed to design nanoparticle-based delivery systems, which improve antigen stability and immunogenicity.

Simulating Vaccine Efficacy

AI, coupled with computer simulations, enables researchers to model vaccine efficacy before moving to the trial phase. These simulations incorporate factors such as antigen selection, delivery mechanisms, immune responses, and other critical aspects, providing a more efficient alternative to traditional experimental methods.

Real-World Applications and Case Studies

AI-Enhanced Neoantigen Prediction

One notable application of AI in cancer vaccine development involves using AI algorithms to identify specific neoantigens for a personalized melanoma vaccine. The T-cells in clinical trials responded to these identified antigens and demonstrated significant tumor reduction, highlighting the potential of AI-enhanced vaccine

development.

BioNTech and Moderna's AI Integration

BioNTech and Moderna are two companies that have integrated AI into their vaccine development systems. AI-powered platforms are used to map tumor mutations and immune responses, enabling the design of patient-specific mRNA vaccines. Early-phase clinical trials, such as those for non-small cell lung cancer, have shown promising results, demonstrating the potential of AI in advancing vaccine development.

Areas of Concern Regarding the Use of AI in Cancer Vaccine Development

Infrastructure of the AI System

AI models require vast amounts of high-quality data. Unfortunately, datasets related to cancer are often heterogeneous, biased, and incomplete, which could lead to inaccurate AI predictions in the future.

Learning Statistically Supported AI Models

Many AI models operate as "black boxes," meaning their predictions are difficult to interpret. It is often unclear why certain antigens are selected or what factors influence the decision-making

process. Efforts to develop explainable AI (XAI) are underway to address this issue, which would provide greater transparency in AI decision-making.

Testing AI-Derived Models

Although AI-derived models can predict antigens and immune responses, they must still undergo preclinical and clinical trials to verify their effectiveness. Implementing AI predictions in real-world patient care is an ongoing challenge.

Future Directions

As AI continues to evolve, its integration with cancer vaccines will be further enhanced by technologies such as CRISPR and single-cell sequencing. AI is also expected to play a critical role in improving adjuvants and delivery systems, thereby boosting vaccine efficacy. Collaboration between computational and immunological research will be crucial to maximize the potential of AI in cancer vaccine development.

Conclusion

AI applications are now actively employed in cancer vaccine development, including antigen screening, immune response prediction, and the functional optimization of vaccines. Despite challenges regarding data quality and validation, AI's ability to accelerate the process and improve vaccine development is undeniable. As

AI technology progresses, it is expected to play a pivotal role in advancing cancer immunotherapy and enhancing the overall efficacy of vaccines.

Future of Vaccination in Breast and Lung Cancer Treatment

Emerging Trends in Personalized Cancer Vaccines Tailored to Individual Genetic Profiles
Potential for Combining Vaccines with Other Therapies such as Immunotherapy and Chemotherapy
Future of Vaccination in Breast and Lung Cancer Treatment

The cancer immunotherapy field holds great promise, with particular optimism for the advancement of vaccination methods in the treatment of breast and lung cancers. These vaccines aim to activate the immune system to identify and destroy tumor cells. Both forms of vaccination seek to enhance patient outcomes, with future steps focused on developing customized cancer vaccines based on genetic profiles and combining these vaccines with other treatment modalities, such as immunotherapy and chemotherapy.

Emerging Trends in Personalized Cancer Vaccines

Genomic Profiling and Neoantigen Discovery

Personalized cancer vaccines represent a form of cancer immunotherapy that utilizes genomic profiling to target tumor antigens, such as neoantigens, which arise due to somatic mutations. Neoantigens are specific to individual tumors, making them ideal targets for generating a strong immune response without harming normal tissue. The application of advanced technologies, such as bioinformatics and next-generation sequencing, is essential to fully understand these antigens and design tailored vaccines.

Personalization Through mRNA Vaccines

Modern approaches to personalized tumor vaccines have introduced mRNA vaccines as a versatile and efficient platform. These vaccines encode neoantigens found in the patient's tumor, allowing for easy manufacture and testing. Clinical data confirm that mRNA vaccines can induce strong T-cell responses specific to patient antigens in cancers such as melanoma and non-small cell lung carcinoma (NSCLC).

Personalization With AI

The role of artificial intelligence (AI) in personalizing cancer vaccines has grown significantly. AI can analyze complex datasets to identify the best combination of antigens. AI algorithms can predict antigen presentation

by major histocompatibility complex (MHC) molecules, allowing for the tailoring of vaccine formulations to each patient's unique needs.

Case Examples: Breast Cancer and Lung Cancer

In early-phase clinical trials, personalized cancer vaccines have shown effectiveness in both breast and lung cancers. For example, in breast cancer, BioNTech has developed an mRNA vaccine, BNT122, which is currently undergoing clinical trials for various cancers, including breast cancer, to determine if it can target specific cancer mutations.

Cancer Vaccines and Immune Therapy

Cancer vaccines are increasingly being used alongside immune checkpoint inhibitors, such as PD-1 and CTLA-4 antibodies, to enhance their efficacy in immunosuppressive tumor microenvironments. Clinical research has shown that while T-cell activation is boosted by vaccines, checkpoint inhibitors continue to block inhibitory signals, allowing for sustained activity.

Further Exploration of Combination Therapies

Significant progress has been made in combining vaccines with chemotherapy. Chemotherapeutic agents are known to induce immunogenic cell

death, which releases tumor antigens that can work synergistically with vaccines to enhance the immune response. For example, combining peptide vaccines with doxorubicin has been shown to increase survival in preclinical models of breast cancer.

Associated with Radiation Therapy

Radiotherapy can also improve vaccine efficacy by aiding the release of antigens and enhancing the tumor's immunogenicity. Combining radiation with cancer vaccines has demonstrated beneficial results, particularly in lung cancer, characterized by improved T-cell infiltration and better local control of the tumor.

Immunotherapies Using Adjuvants and Combination with Other Strategies

Researchers are investigating adjuvants, such as toll-like receptor (TLR) agonists, to enhance the activity of cancer vaccines. These adjuvants can activate dendritic cells and improve antigen presentation, making them promising candidates for combination with vaccines in the treatment of breast and lung cancers.

Challenges and Future Opportunities

Tumor Heterogeneity in Breast and Lung Cancers

A significant challenge in vaccine development is tumor heterogeneity in breast and lung cancers. While patient-specific neoantigen vaccines hold great potential, substantial development and validation are still required.

Vaccine Distribution

Advancements in nanotechnology, particularly in lipid nanoparticle (LNP) systems, are improving the delivery, stability, and production of cancer vaccines. These delivery systems enhance uptake by antigen-presenting cells, triggering a robust immune response.

Synergy with Multiple Modalities

The future success of cancer vaccines lies in their combination with targeted therapies and hormone treatments for breast cancer. Positive results have been observed when vaccines are used alongside HER2-targeted therapies, such as trastuzumab, in HER2-positive breast cancer.

Conclusion

Summary of the Significance of Innovative Vaccination in Combating Breast and Lung Cancers

Emphasis on the Need for Further Research and Investment to Improve Patient Outcomes

Specialized vaccination techniques targeting breast and lung cancers have introduced new avenues for more precise and effective cancer therapies. These vaccines represent a significant leap forward in cancer treatment, leveraging advanced technologies such as mRNA platforms, designer antigens, and lipid nanoparticle delivery systems. Notably, the mRNA vaccine developed for HER2-positive breast cancer and non-small cell lung cancer (NSCLC) has demonstrated strong efficacy in eliciting immune responses specific to these cancer types, showing promising clinical results for the future.

Despite these advances, challenges such as tumor heterogeneity, immune evasion, and the suppressive nature of the tumor microenvironment continue to hinder the widespread adoption of these vaccines in routine clinical practice. Furthermore, several researchers have highlighted the dysregulation of SUMO (Small Ubiquitin-like Modifier) regulators as an important factor in oncogenesis and cancer therapy. Disruptions in the tumor-associated SUMO pathway could be leveraged to enhance vaccine formulation and effectiveness, particularly when combined with immune therapies.

Looking ahead, the next crucial step in cancer vaccine development is securing substantial investments in clinical and translational research. Cancer vaccines are likely to yield more significant

effects when integrated with checkpoint inhibitors, targeted therapies, or other forms of immunotherapy. Such combination treatment strategies not only have the potential to enhance therapeutic outcomes but also to alleviate the suffering of cancer patients. Innovations in vaccine technology are set to transform the current landscape of cancer management, shifting the focus towards more personalized and combination-based approaches to cancer treatment.

5- INNOVATIVE VACCINATION FOR ORAL CANCERS

Background

Although the incidence of head and neck squamous cell carcinoma (HNSCC) has declined in recent decades, the incidence of oropharyngeal cancer (OPC), a subcategory of HNSCC, has increased. The primary etiology of OPC in 70-90% of cases is human papillomavirus (HPV). Since most of the affected patients are younger, healthier, and non-smokers, there is growing interest in investigating the potential effects of the HPV vaccine.

While HPV vaccination is a preventive strategy for cervical cancer, there are still gaps in research regarding the role of HPV vaccination in preventing HPV-associated OPC. This is particularly relevant considering that the rate of vaccination in men is lower than in women. Oral HPV infection is 2.3 times more common in men than in women, which could be attributed to limited antibody formation to HPV in men and the higher transferability of infection during oral sex with a female partner. This highlights the increasing need for a comprehensive, pangender HPV vaccination strategy.

Philip Macilwraith et al. (2023) conducted a

review of seven relevant articles to investigate the potential impacts of the HPV vaccine on preventing OPC in men. They concluded that a pangender HPV vaccination approach is beneficial, particularly in terms of risk reduction and cost-effectiveness, especially in higher-income countries.

In another systematic review, Nielsen et al. (2021) emphasized the impact of HPV vaccination on oral HPV. A total of nine studies, involving 48,777 participants, were analyzed. The results showed a substantial decrease in oral HPV positivity, with a mean Relative Prevention Percentage (RPP) ranging from 82.4% to 83.9% following vaccination.

However, given the limited number of studies on the beneficial impacts of the HPV vaccine for OPC, further controlled trials are necessary to investigate the effects of vaccinating men for HPV and the subsequent consequences on OPC development. It would be sensible to suggest that vaccinating both men and women against HPV could help reduce the future incidence of HPV-associated OPC.

Mechanisms of Cancer Vaccination

The immune system plays a critical role in recognizing and eliminating abnormal or foreign cells. However, cancer cells often develop mechanisms to evade immune detection, allowing

them to grow and proliferate unchecked. Cancer vaccines are designed to overcome these barriers by activating and directing the immune system toward tumor-specific targets.

The primary mechanisms by which cancer vaccines exert their effects include:

Activation of Antigen-Presenting Cells (APCs) – Cancer vaccines introduce tumor antigens into the body, which are processed by APCs such as dendritic cells. These cells then present the antigens to T-cells, initiating an immune response.

Stimulation of Cytotoxic T-Lymphocyte (CTL) Responses – CD8+ T-cells, also known as cytotoxic T lymphocytes, play a central role in tumor cell destruction. Cancer vaccines enhance CTL activation, enabling them to recognize and kill cancerous cells more effectively.

Enhancement of Helper T-Cell (CD4+) Activity – Helper T-cells assist in the coordination of immune responses by activating other immune cells, including B-cells and macrophages, leading to a more robust anti-tumor effect.

Overcoming Immune Suppression – Tumors create an immunosuppressive microenvironment by releasing inhibitory cytokines and recruiting regulatory T-cells (Tregs). Cancer vaccines can be designed to counteract these suppressive effects, allowing the immune system to remain active against the tumor.

Inducing Immune Memory – One of the most

promising aspects of cancer vaccination is the ability to generate long-term immune memory. This ensures that the immune system remains vigilant against cancer recurrence, offering sustained protection.

Innovative Vaccination Strategies for Oral Cancer

Peptide-Based Vaccines

Peptide-based vaccines are among the most extensively studied cancer vaccines. These vaccines utilize short amino acid sequences derived from tumor-specific or tumor-associated antigens to elicit an immune response. The goal is to stimulate cytotoxic T-cell activation, leading to the selective destruction of cancer cells.

Several tumor-associated antigens have been identified in oral cancers, including:

Mucin-1 (MUC1) – A glycoprotein overexpressed in oral squamous cell carcinoma (OSCC).

Epidermal Growth Factor Receptor (EGFR) – Frequently upregulated in head and neck cancers.

Human Papillomavirus (HPV) E6 and E7 Proteins – Critical in HPV-associated oral cancers.

Wilms' Tumor 1 (WT1) – A tumor suppressor protein often mutated in oral cancer.

Peptide vaccines have shown promise in preclinical and early clinical trials. However, one of the challenges is that peptide-based vaccines may only work effectively in individuals with

specific human leukocyte antigen (HLA) types, limiting their broad applicability. Additionally, peptide vaccines often require the use of immune adjuvants, such as toll-like receptor (TLR) agonists, to enhance their immunogenicity.

Dendritic Cell (DC) Vaccines

Dendritic cells are the most potent antigen-presenting cells in the immune system. DC vaccines are designed by isolating dendritic cells from the patient, loading them with tumor antigens ex vivo, and then reinfusing them into the patient to trigger a robust anti-tumor response.

In oral cancer, dendritic cell vaccines have been tested in various clinical settings:

DCs loaded with HPV E6/E7 peptides have been evaluated in HPV-positive oral cancers, demonstrating strong T-cell responses.

DCs pulsed with OSCC tumor lysates have led to increased survival rates in animal models.

Combination therapies with immune checkpoint inhibitors (e.g., anti-PD-1 antibodies) have shown potential in overcoming immune suppression.

DC vaccines represent a highly personalized form of immunotherapy, but their development and administration are complex and costly, which has limited their widespread clinical use.

DNA and RNA-Based Vaccines

DNA and RNA vaccines introduce genetic material encoding tumor antigens into host cells, leading to the production of tumor-specific proteins that trigger an immune response.

Advantages of DNA/RNA vaccines in oral cancer include:

Durable immune response – DNA vaccines can stimulate long-term immune memory.

Rapid adaptability – RNA vaccines can be quickly modified to target different tumor antigens.

Minimal risk of integration into the host genome – Unlike viral vectors, mRNA vaccines do not carry the risk of permanent genetic alteration.

Recent studies have shown promising results with DNA vaccines encoding EGFR and HPV antigens in oral cancers. Additionally, RNA vaccines encoding neoantigens unique to individual tumors are being explored as a form of personalized immunotherapy.

Oncolytic Virus Vaccines

Oncolytic viruses are genetically engineered to selectively infect and kill cancer cells while triggering an immune response. These viruses can also be modified to express tumor antigens, enhancing their immunogenicity.

Examples of oncolytic virus vaccines in oral cancer research include

Herpes Simplex Virus (HSV-1) derivatives –

Engineered to target OSCC cells while sparing normal tissues.

Adenoviruses encoding HPV antigens – Studied in HPV-positive head and neck cancers.

Reoviruses – Explored for their ability to exploit oncogenic pathways in oral cancer cells.

Clinical trials have indicated that oncolytic viruses can be effective in reducing tumor size and improving survival in patients with advanced oral cancer, particularly when combined with immune checkpoint blockade therapies.

Whole Tumor Cell Vaccines

Whole tumor cell vaccines utilize inactivated cancer cells from the patient or a tumor cell line to stimulate an immune response against multiple tumor-associated antigens simultaneously. These vaccines can be modified to enhance antigen presentation and improve immune activation.

Recent studies in oral cancer suggest that whole tumor cell vaccines may provide broad-spectrum immunity and reduce the likelihood of immune escape mechanisms. However, their use in clinical practice is still limited due to the complexity of manufacturing and standardization.

Future Directions and Challenges

While innovative vaccination strategies for oral cancer hold great promise, several challenges remain:

Heterogeneity of Oral Cancers – The diverse

genetic and molecular profiles of oral cancers make it difficult to develop a one-size-fits-all vaccine.

Immune Evasion by Tumors – Some tumors develop mechanisms to suppress immune responses, requiring combination therapies for optimal effectiveness.

Clinical Trial Limitations – Many novel vaccines are still in early-stage trials, and large-scale validation is needed.

Manufacturing and Cost Issues – Personalized vaccines such as DC and tumor lysate vaccines remain expensive and resource-intensive.

Despite these challenges, the future of oral cancer vaccination is promising. Advances in neoantigen identification, artificial intelligence-driven vaccine design, and combination immunotherapies will likely revolutionize the field in the coming years, offering more effective and accessible treatment options for patients.

6- INNOVATIVE VACCINATION FOR HEAD AND NECK CANCERS

Background

Head and neck squamous cell carcinoma (HNSCC), originating from the squamous cells of the oral cavity, pharynx, and larynx, is the sixth most common neoplasm worldwide. With a 5-year survival rate of 50%, it has one of the lowest survival rates among major cancers. This trend can be partly attributed to lifestyle changes, such as increased alcohol consumption and tobacco use in developing nations, alongside the rising prevalence of human papillomavirus (HPV)-related oropharyngeal cancer. It is anticipated that HPV will surpass tobacco as the primary contributor to the global HNSCC burden, leading to the incidence of oropharyngeal HNSCC exceeding that of oral cancer, which is predominantly tobacco-related.

Human papillomavirus (HPV) is a non-enveloped, double-stranded DNA virus and the most common sexually transmitted infection worldwide. Primary prevention of HPV can be achieved through abstinence or vaccination prior to sexual activity. Vaccination is among the most promising and cost-effective methods for protecting individuals from infectious diseases

and cancers, contributing to the eradication of diseases.

The goal of cancer vaccination is to achieve anticancer effects by activating or enhancing an effective CD4+/CD8+ antigen-specific T-cell response. Vaccination is commonly accomplished by injecting peptides or antigen-encoding DNA or RNA. Peptide-based vaccines are one of the most widely utilized strategies for cancer vaccination. The ideal properties of vaccine peptides include cancer cell-specific expression, high immunogenicity, and, ideally, a functional dependency specific to cancer cells. Antigens used for treatment are generally divided into tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs).

Currently, several therapeutic peptide vaccines are under investigation for HNSCC. For instance, Trojan peptide-based vaccines have been designed for advanced HNSCC patients. These vaccines include HLA-I and HLA-II restricted peptide epitopes, such as melanoma antigen E (MAGE-A3) and HPV-16 TAA, respectively. These vaccines have also been evaluated in phase 1 clinical trials in advanced HNSCC patients, where they were found to induce antibody responses and antigen-specific T-cell responses in most patients.

Research by Chai et al. demonstrated that after PV1 vaccination, patients' T-cells released cytotoxic cytokines. Moreover, patients with

significant MAGED4B and FJX1 expression in their tumors were more sensitive to PV1 activation, highlighting the PV1 peptide vaccine's specificity. PV1 shows potential as a promising vaccination candidate for HNSCC patients and other malignancies expressing these antigens. Placenta-specific 1 (PLAC1) is another target for cancer immunotherapy. Expressed primarily in placental trophoblasts but not in normal tissues, PLAC1 has been detected in 74.5% of oropharyngeal tumors and 51.9% of oral cavity tumors, as well as in many HNSCC cell lines. Researchers have also identified an HTL peptide epitope (PLAC131-50) capable of inducing potent T-cell responses, suggesting that PLAC1 could serve as a target antigen for HNSCC patients.

One advantage of nucleic acid-derived vaccines is that DNA and RNA vaccines can be synthesized more easily and quickly than peptide vaccines, although they carry a risk of genetic recombination. DNA vaccines, which are made from bacterial plasmids encoding antigens, are often paired with immune-stimulatory molecules such as IL-2 and granulocyte/macrophage colony-stimulating factor. The Ii-PADRE-E6 DNA vaccine represents a novel immunotherapeutic strategy that enhances E6-specific CD8+ T-cell responses via PADRE-specific CD4+ T-helper cells. The success of the Ii-PADRE-E6 DNA vaccine in preclinical mouse models has laid a foundation

for its clinical translation in controlling HPV-associated head and neck cancers in humans. As most HPV-associated head and neck cancers are related to HPV type-16, this DNA vaccine targeting HPV-16 E6 holds significant promise.

Additionally, studies confirm that pDom-M/F DNA vaccines significantly reduce tumor burden, an effect further enhanced when combined with anti-PD1 antibodies, achieving complete tumor clearance in 50% to 75% of mice in BAF and BAM models, respectively.

A trending subject in cancer immunotherapy is the development of mRNA vaccines. These vaccines represent an innovative and dynamic approach to cancer treatment and have shown great potential in improving immunotherapeutic outcomes.

Mechanisms of Cancer Vaccination

Cancer vaccines function by harnessing the immune system to recognize and attack cancer cells. Unlike traditional treatments that directly target tumors, cancer vaccines stimulate the body's natural defenses to achieve a sustained immune response. The key mechanisms through which cancer vaccines exert their effects include:

Activation of Antigen-Presenting Cells (APCs) – Cancer vaccines introduce tumor antigens into the body, which are processed by antigen-presenting

cells such as dendritic cells and macrophages. These cells then present the antigens to T-cells, initiating an immune response.

Stimulation of Cytotoxic T-Lymphocyte (CTL) Responses – CD8+ T-cells, also known as cytotoxic T lymphocytes, are the primary effectors in tumor cell destruction. Cancer vaccines enhance CTL activation, enabling them to recognize and kill cancerous cells more effectively.

Enhancement of Helper T-Cell (CD4+) Activity – Helper T-cells play a crucial role in coordinating the immune response by activating other immune cells, including B-cells and macrophages, leading to a more robust anti-tumor effect.

Overcoming Immune Suppression – Tumors create an immunosuppressive microenvironment by releasing inhibitory cytokines and recruiting regulatory T-cells (Tregs). Cancer vaccines can be designed to counteract these suppressive effects, allowing the immune system to remain active against the tumor.

Inducing Immune Memory – One of the most promising aspects of cancer vaccination is the ability to generate long-term immune memory. This ensures that the immune system remains vigilant against cancer recurrence, offering sustained protection.

Innovative Vaccination Strategies for Head and Neck Cancer

Peptide-Based Vaccines

Peptide-based vaccines are designed to stimulate an immune response by introducing small protein fragments derived from tumor-specific or tumor-associated antigens. These vaccines work by activating cytotoxic T-cells, which then recognize and attack cancerous cells expressing the targeted antigen.

In head and neck cancers, several peptide-based vaccines have been developed, targeting key tumor antigens such as:

Human Papillomavirus (HPV) E6 and E7 Proteins – HPV infection is a major cause of oropharyngeal cancers. Peptide vaccines targeting the E6 and E7 oncoproteins have shown promise in inducing an immune response against HPV-associated tumors.

Epidermal Growth Factor Receptor (EGFR) – EGFR is overexpressed in many head and neck cancers, making it a viable target for peptide-based vaccines.

MAGE Family Antigens (Melanoma-Associated Antigens) – These antigens are expressed in various head and neck tumors and have been investigated as vaccine targets.

Peptide vaccines have demonstrated encouraging results in preclinical and early clinical trials. However, one limitation is their dependence on the patient's human leukocyte antigen (HLA) type, which may restrict their applicability across diverse populations. Additionally, peptide

vaccines often require adjuvants, such as toll-like receptor (TLR) agonists, to enhance their immunogenicity.

Dendritic Cell (DC) Vaccines

Dendritic cells are the most potent antigen-presenting cells in the immune system. DC vaccines involve isolating dendritic cells from the patient, loading them with tumor antigens ex vivo, and reinfusing them to trigger a robust anti-tumor immune response.

In head and neck cancers, dendritic cell vaccines have been explored in various clinical settings:

DCs loaded with HPV E6/E7 peptides have been tested in HPV-positive head and neck cancers, demonstrating strong T-cell responses.

DCs pulsed with tumor lysates from head and neck squamous cell carcinoma (HNSCC) have shown promising results in clinical trials.

Combination therapies with immune checkpoint inhibitors (e.g., anti-PD-1 antibodies) have been evaluated to enhance the efficacy of DC vaccines.

While DC vaccines offer a highly personalized approach to cancer immunotherapy, their development and administration are complex and costly, which has limited their widespread clinical use.

DNA and RNA-Based Vaccines

DNA and RNA vaccines introduce genetic material encoding tumor antigens into host cells, leading

to the production of tumor-specific proteins that trigger an immune response.

Advantages of DNA/RNA vaccines include:

Long-lasting immune response – DNA vaccines can stimulate durable immunity.

Rapid adaptability – RNA vaccines can be quickly modified to target different tumor antigens.

Minimal risk of integration into the host genome – Unlike viral vector-based vaccines, mRNA vaccines do not carry the risk of permanent genetic alteration.

Several DNA and RNA vaccines targeting HPV-associated head and neck cancers have been developed. Clinical trials have shown that these vaccines can elicit strong immune responses, particularly when combined with checkpoint inhibitors.

Oncolytic Virus Vaccines

Oncolytic viruses are genetically engineered to selectively infect and destroy cancer cells while stimulating an immune response. These viruses can also be modified to express tumor antigens, enhancing their immunogenicity.

Examples of oncolytic virus vaccines in head and neck cancer research include:

Herpes Simplex Virus (HSV-1) derivatives – Engineered to target head and neck squamous cell carcinoma cells while sparing normal tissues.

Adenoviruses encoding HPV antigens – Studied in HPV-positive head and neck cancers.

Reoviruses – Explored for their ability to exploit oncogenic pathways in HNSCC.

Clinical trials have indicated that oncolytic viruses can be effective in reducing tumor size and improving survival in patients with advanced head and neck cancer, particularly when combined with immune checkpoint blockade therapies.

Future Directions and Challenges

While innovative vaccination strategies for head and neck cancers hold great promise, several challenges remain:

Heterogeneity of Head and Neck Cancers – The diverse genetic and molecular profiles of these cancers make it difficult to develop a universally effective vaccine.

Immune Evasion Mechanisms – Some tumors develop mechanisms to suppress immune responses, requiring combination therapies for optimal effectiveness.

Clinical Trial Limitations – Many novel vaccines are still in early-stage trials, and large-scale validation is needed.

Manufacturing and Cost Issues – Personalized vaccines such as dendritic cell and tumor lysate vaccines remain expensive and resource-intensive.

Despite these challenges, the future of vaccination for head and neck cancers is promising. Ongoing advancements in neoantigen identification,

artificial intelligence-driven vaccine design, and combination immunotherapies will likely lead to more effective and accessible treatments in the coming years.

7- INNOVATIVE VACCINATION FOR UROGENITAL CANCERS

Background

Urogenital cancers, which include malignancies of the urinary tract and reproductive organs, represent a diverse group of tumors that impact both men and women. These cancers are often diagnosed at advanced stages and have poor prognoses, particularly for those that are not amenable to traditional treatments such as surgery, chemotherapy, and radiation. The urogenital system encompasses the kidneys, bladder, prostate, testes, ovaries, uterus, cervix, and vulva, each of which can develop different forms of cancer with distinct molecular and clinical features.

Among the most common urogenital cancers are bladder cancer, prostate cancer, renal cell carcinoma (RCC), and cancers of the female reproductive system, including cervical, ovarian, and endometrial cancers. Bladder cancer, for example, is among the most common cancers in both men and women, while prostate cancer remains the most frequently diagnosed cancer in men. Additionally, human papillomavirus (HPV) is a major causative agent in cervical cancer, which remains one of the leading causes of cancer-

related deaths in women worldwide.

The treatment landscape for urogenital cancers has evolved significantly in recent years with the advent of targeted therapies, immune checkpoint inhibitors, and other immunotherapeutic strategies. However, despite these advancements, there remains a need for more effective and less toxic treatments to improve patient outcomes. One promising approach that has garnered significant attention is the development of cancer vaccines. Unlike traditional cancer therapies, cancer vaccines are designed to stimulate the body's immune system to recognize and attack tumor cells, offering the potential for more specific and sustained anti-tumor immunity.

Vaccination for urogenital cancers is still in its nascent stages, but recent innovations in vaccine platforms have opened new possibilities for both preventive and therapeutic vaccination. These vaccines aim to target specific tumor antigens, including those associated with viral infections like HPV and antigens expressed by urogenital cancer cells. The development of effective vaccines for urogenital cancers has the potential to revolutionize the way these cancers are treated, reduce recurrence rates, and improve survival outcomes.

This chapter explores the innovative vaccination strategies currently being researched for urogenital cancers. It examines the underlying mechanisms of these vaccines, reviews the most

promising vaccine candidates and platforms, discusses clinical trial results, and highlights the challenges faced in developing and implementing these therapies. Finally, the chapter looks toward the future of cancer vaccination in urogenital malignancies and the potential for these therapies to reshape cancer treatment paradigms.

Mechanisms of Cancer Vaccination

Cancer vaccines work by stimulating the immune system to recognize and attack cancer cells. These vaccines introduce tumor-specific antigens or tumor-associated antigens (TAAs) into the body, triggering an immune response that targets and destroys cancer cells. Unlike traditional vaccines that are used to prevent infectious diseases, cancer vaccines can be classified into two broad categories: preventive and therapeutic vaccines.

Preventive Vaccines

Preventive vaccines aim to stop cancer from developing in the first place by inducing immunity against viruses or other pathogens that contribute to cancer formation. The most well-known example of a preventive cancer vaccine is the HPV vaccine, which prevents cervical, anal, and other HPV-related cancers. These vaccines work by stimulating the immune system to produce antibodies against the viral proteins responsible for causing cellular transformations that lead to

cancer. The HPV vaccine, which targets the E6 and E7 oncoproteins of HPV types 16 and 18, has already had a significant impact in reducing the incidence of cervical cancer worldwide.

Preventive vaccines for other urogenital cancers are being explored, particularly those caused by infectious agents such as HPV and hepatitis B virus (HBV). By preventing the viral infections that are linked to the development of urogenital cancers, these vaccines could significantly reduce the incidence of these cancers, especially in high-risk populations.

Therapeutic Vaccines

Therapeutic vaccines, on the other hand, are designed to treat existing cancers by boosting the immune system's ability to recognize and target tumor cells. These vaccines generally work by introducing antigens associated with the tumor into the body, which stimulates an immune response. The immune system then activates cytotoxic T lymphocytes (CTLs) and other immune cells to recognize and kill the tumor cells. Therapeutic cancer vaccines can be categorized into several types, including peptide-based vaccines, dendritic cell vaccines, DNA/RNA vaccines, and viral vector vaccines. These vaccines can target tumor antigens such as cancer-testis antigens (CTAs), tumor-associated antigens (TAAs), and neoantigens that are unique to the cancer cells of a patient.

For urogenital cancers, therapeutic vaccination strategies are actively being developed to target antigens that are specifically expressed in tumor cells. For example, in bladder cancer, antigens such as HER2 and mucin 1 (MUC1) have been identified as potential targets for vaccine development. Likewise, in prostate cancer, the prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) are prime targets for therapeutic vaccines.

The goal of these vaccines is to generate an immune response that can target and destroy the cancer cells while minimizing damage to healthy tissues. One of the key challenges in developing therapeutic vaccines is overcoming the immune suppressive environment of the tumor, which can dampen the effectiveness of the immune response. Researchers are investigating various approaches to enhance vaccine efficacy, including the use of adjuvants, immune checkpoint inhibitors, and combination therapies.

Innovative Vaccination Strategies for Urogenital Cancers

HPV Vaccines for Cervical Cancer and Other HPV-Related Cancers

Human papillomavirus (HPV) infection is the leading cause of cervical cancer, as well as other urogenital malignancies such as anal and oropharyngeal cancers. The development of vaccines against HPV has revolutionized the

prevention of these cancers. The first HPV vaccines, Gardasil and Cervarix, have shown remarkable success in preventing cervical cancer by inducing an immune response against the HPV types 16 and 18, which are responsible for the majority of HPV-related cancers.

In addition to preventing the development of cervical cancer, the HPV vaccine has the potential to prevent other cancers caused by HPV, including those of the anus, vulva, and vagina. New HPV vaccines are also being developed to cover a broader range of HPV types, including those associated with a higher risk of cancer. These vaccines have the potential to significantly reduce the incidence of HPV-related urogenital cancers, particularly when administered to adolescents and young adults prior to exposure to the virus.

The success of preventive HPV vaccines has spurred interest in developing therapeutic vaccines for patients already infected with HPV. These vaccines aim to treat existing infections and cancer by stimulating the immune system to target HPV-infected cells. HPV therapeutic vaccines focus on the E6 and E7 oncoproteins, which are expressed in HPV-related tumors, and are being tested in clinical trials for their ability to induce immune responses capable of eliminating infected cells.

Vaccines for Bladder Cancer

Bladder cancer is a major urogenital malignancy

with high recurrence rates, and the treatment options for advanced disease are limited. Bladder cancer is often characterized by the overexpression of certain tumor antigens, such as HER2, MUC1, and survivin, making it a prime candidate for therapeutic vaccination strategies. Several vaccine candidates targeting these antigens are currently being investigated.

One promising approach is the development of peptide-based vaccines that target tumor antigens specific to bladder cancer. These vaccines are designed to stimulate the immune system to recognize and attack bladder cancer cells expressing these antigens. Additionally, dendritic cell vaccines are being explored, where dendritic cells are loaded with tumor lysates or peptides and then reinfused into the patient to boost the immune response.

A number of clinical trials have explored the use of Bacillus Calmette-Guérin (BCG) therapy, which involves instilling weakened bacteria into the bladder to stimulate an immune response. While BCG is primarily used for its immune-stimulating properties in superficial bladder cancer, researchers are investigating ways to combine BCG with tumor-specific vaccines to enhance their effectiveness.

Prostate Cancer Vaccines

Prostate cancer is one of the most common cancers in men and is often diagnosed at

an advanced stage, leading to high mortality. Vaccines targeting prostate-specific antigens such as prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) have been under investigation for many years. These vaccines aim to stimulate an immune response that targets prostate cancer cells expressing these antigens.

One of the most widely studied prostate cancer vaccines is Provenge (sipuleucel-T), which is an autologous dendritic cell-based vaccine. Provenge has been shown to prolong survival in patients with metastatic prostate cancer by stimulating the immune system to target prostate cancer cells. This vaccine is a personalized approach that involves extracting dendritic cells from the patient, exposing them to PAP, and then reintroducing them into the patient to provoke an immune response.

Other novel vaccine approaches for prostate cancer include the use of DNA vaccines and viral vector-based vaccines. DNA vaccines encoding prostate cancer antigens are designed to induce long-term immunity, while viral vector-based vaccines utilize engineered viruses to deliver tumor antigens directly into the body, stimulating an immune response.

Renal Cell Carcinoma (RCC) Vaccines

Renal cell carcinoma (RCC) is a common and aggressive form of kidney cancer, and

despite advancements in targeted therapies, the prognosis for patients with metastatic disease remains poor. RCC is known for its immune-suppressive microenvironment, which hinders the effectiveness of many therapies. Therefore, immune-based strategies, including vaccination, are being explored as potential treatments.

RCC vaccines are typically designed to target tumor antigens such as CA-IX, MAGE-A3, and VEGF (vascular endothelial growth factor). These antigens are overexpressed in RCC cells and are being targeted through peptide-based vaccines, dendritic cell vaccines, and DNA vaccines. In preclinical models, these vaccines have shown the ability to induce a specific immune response that can target and destroy RCC cells.

Ovarian Cancer Vaccines

Ovarian cancer is a leading cause of gynecological cancer death, often diagnosed at advanced stages. Vaccination strategies for ovarian cancer focus on antigens such as CA-125, MUC1, and NY-ESO-1, which are overexpressed in ovarian tumors. Vaccines targeting these antigens aim to boost the immune system's ability to recognize and attack ovarian cancer cells.

In clinical trials, both peptide-based and dendritic cell-based vaccines have shown promise in eliciting an immune response against ovarian cancer. Researchers are also exploring the combination of vaccines with immune checkpoint

inhibitors, which could help overcome the immune suppression that occurs within the tumor microenvironment.

8- INNOVATIVE VACCINATION FOR BONE CANCERS

Background

Bone cancers, while less common than many other malignancies, pose significant treatment challenges and have a severe impact on the lives of affected individuals. Recent advancements in immunotherapy, particularly vaccine-based approaches, have generated considerable interest in developing novel therapeutic strategies for these aggressive tumors. This review synthesizes findings from recent scholarly articles available on PubMed and Scopus regarding vaccination strategies targeting bone cancers.

Osteosarcoma and Ewing sarcoma are the two primary types of bone cancers, predominantly affecting pediatric and adolescent populations. Although surgical interventions and chemotherapy have improved treatment outcomes, the prognosis for patients with metastatic disease remains disheartening. The emergence of drug resistance and the adverse effects associated with conventional therapies underscore the urgent need for alternative treatment modalities. Cancer vaccination has shown potential as a means of stimulating the immune system to recognize and combat cancer-

specific antigens.

Bone cancers, though relatively rare, present significant clinical challenges due to their aggressive nature and the complexity of treatment. Osteosarcoma and Ewing's sarcoma are the most commonly diagnosed types of bone cancers, primarily affecting children and young adults. Both malignancies often metastasize at advanced stages, complicating the prognosis and treatment efficacy. The traditional treatment regimen, which typically involves surgical intervention, chemotherapy, and radiation therapy, is not always sufficient, especially in cases of recurrence or metastasis. This highlights the need for novel therapeutic strategies that could improve survival rates and quality of life for patients.

In recent years, cancer immunotherapy has emerged as a promising alternative to conventional treatments, offering new hope for patients with limited therapeutic options. Immunotherapy aims to leverage the body's immune system to fight cancer by stimulating the immune response against tumor cells. Among the most innovative immunotherapy strategies are cancer vaccines, which are designed to promote the immune system’s recognition and destruction of cancer cells. Vaccination in oncology has gained substantial attention as a potential tool for not only preventing cancer but also treating existing

tumors, including those in bone.

This chapter delves into the innovative vaccination strategies for bone cancers, focusing on the mechanisms behind cancer vaccines, the challenges associated with developing effective vaccines for osteosarcoma and Ewing's sarcoma, and the progress made in clinical and preclinical studies. By exploring current research, this chpater aims to provide an in-depth understanding of the potential and the hurdles of vaccination-based therapies in the treatment of bone cancers.

Mechanisms of Action

Cancer vaccines are designed to enhance the body's immune response to recognize and eliminate tumor cells. These vaccines can be classified into several categories:

Peptide-Based Vaccines: These vaccines employ specific peptides derived from tumor-associated antigens (TAAs) to provoke an immune response. In bone cancers, peptides such as osteopontin and MAGE family antigens have been the focus of research.

Dendritic Cell Vaccines: Dendritic cells, which are potent antigen-presenting cells (APCs), are loaded with TAAs to enhance T-cell responses against cancer cells.

DNA Vaccines: This approach utilizes plasmid

DNA encoding tumor antigens to induce a cytotoxic T lymphocyte (CTL) response. DNA vaccines have attracted increasing interest due to their potential to induce long-term immunity.

Oncolytic Virus Vaccines: These genetically modified viruses specifically target and destroy cancer cells while simultaneously stimulating immune responses, providing a dual mechanism of action.

Recent Advances in Vaccination for Bone Cancer

Several recent studies have highlighted notable progress in the development of vaccination strategies for bone cancers, both in preclinical and clinical trials.

Peptide-Based Vaccines

Various clinical trials have investigated peptide-based vaccines targeting specific antigens in osteosarcoma. For example, research on HLA-A2-restricted peptides derived from MAGE-A3 has shown promising results, with patients exhibiting enhanced T-cell responses that correlate with improved survival rates.

Dendritic Cell Vaccines

Dendritic cell vaccines have demonstrated the ability to strengthen immune responses in patients with Ewing sarcoma. A recent phase

I clinical trial found that patients receiving dendritic cells loaded with tumor lysates exhibited increased T-cell responses and disease stabilization.

DNA and RNA Vaccines

The effectiveness of DNA vaccines in inducing antitumor immunity has been demonstrated in multiple animal studies. A recent investigation using a plasmid encoding human osteopontin showed significant antitumor effects, particularly when combined with immune checkpoint inhibitors.

DNA and RNA vaccines represent cutting-edge technologies in cancer immunotherapy. These vaccines work by introducing genetic material encoding tumor antigens directly into the body. The body's cells then take up this genetic material and begin producing the tumor antigen, which is then presented to the immune system, stimulating a response.

For bone cancers, DNA and RNA vaccines can be designed to encode specific antigens, such as osteopontin or MAGE-A3. Once injected into the patient, these vaccines trigger an immune response, causing the production of antigen-specific antibodies and cytotoxic T-cells capable of targeting and killing tumor cells. One of the key advantages of DNA and RNA vaccines is that they can be rapidly designed and manufactured,

making them particularly appealing for treating rare cancers like osteosarcoma.

RNA vaccines, in particular, have gained attention in recent years due to their success in other areas, most notably with the COVID-19 vaccines. While still in the experimental phase for bone cancers, RNA vaccines hold promise due to their ability to induce a strong immune response and their relatively simple production process.

Oncolytic Virus Vaccines

Oncolytic viruses are genetically modified viruses that selectively infect and kill cancer cells. These viruses are engineered to replicate within tumor cells, causing cell death, and simultaneously activating the body's immune system to recognize and destroy the cancer cells. The use of oncolytic viruses as a form of vaccination offers a dual mechanism of action—direct tumor lysis and immune activation.

In bone cancers, oncolytic viruses like the vesicular stomatitis virus (VSV) and adenoviruses have shown promise in preclinical studies. These viruses selectively infect osteosarcoma cells, causing them to rupture and release tumor antigens that further stimulate an immune response. Moreover, the immune activation caused by the virus can enhance the effectiveness of other immunotherapies, such as checkpoint inhibitors, leading to a more robust antitumor response.

Challenges and Future Directions

Despite these advancements, several challenges remain in optimizing vaccination strategies for bone cancers:

Tumor Heterogeneity: The variability in TAA expression among patients complicates the development of universally effective vaccines.

Immune Evasion: Bone tumors employ mechanisms to evade immune detection, necessitating the combination of vaccines with immune checkpoint inhibitors to enhance therapeutic efficacy.

Clinical Trial Design: Defining appropriate endpoints and selecting suitable patient populations are crucial for accurately assessing vaccine efficacy and safety in clinical trials.

Conclusion

Innovative vaccination approaches for bone cancers offer exciting prospects for the future of cancer therapy. With continued research into peptide-based vaccines, dendritic cell vaccines, DNA/RNA vaccines, and oncolytic virus therapies, the potential to improve outcomes for patients with osteosarcoma and Ewing's sarcoma is growing. However, significant challenges remain, particularly with regard to tumor heterogeneity, immune evasion, and the complexity of vaccine development.

As the understanding of immune responses to bone tumors deepens, and as new technologies and strategies emerge, cancer vaccines could become an integral part of the treatment landscape for bone cancers. In combination with other immunotherapies and traditional treatments, vaccines have the potential to revolutionize the way we treat these aggressive and devastating diseases.

Ultimately, the future of cancer vaccination for bone cancers holds great promise, and continued research and clinical trials will be essential in bringing these innovative therapies from the laboratory to the clinic.

9- INNOVATIVE VACCINATION FOR OTHER CANCERS

Background

Hematologic cancers, also known as blood cancers, are malignancies that affect the blood, bone marrow, lymphatic system, and spleen. The major categories of hematologic cancers include leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, and myeloproliferative disorders. These cancers arise from the uncontrolled growth of abnormal blood cells, which can disrupt normal immune function and lead to a variety of clinical symptoms and complications. Unlike solid tumors, hematologic cancers primarily involve the cells of the immune system and the bone marrow, which makes them unique in terms of both diagnosis and treatment strategies.

Traditional treatment approaches for hematologic cancers involve chemotherapy, radiation therapy, stem cell transplants, and targeted therapies. However, despite significant advancements, the recurrence of these cancers remains a major concern, and many patients experience side effects and drug resistance. In light of these challenges, innovative treatment strategies, including immunotherapy and vaccination, have

garnered increasing attention in recent years.

Vaccination, an approach that stimulates the immune system to recognize and destroy cancer cells, represents a promising frontier in the treatment of hematologic cancers. The idea behind cancer vaccines is to harness the body's immune response to target specific antigens that are unique to cancerous cells, thereby preventing cancer growth and metastasis. In hematologic cancers, this approach is particularly compelling due to the role of immune cells in the pathophysiology of these diseases.

This article delves into the emerging role of innovative vaccination strategies for hematologic cancers. It explores how cancer vaccines are being developed, the types of vaccines being studied, and the ongoing challenges that need to be addressed for these therapies to become mainstream treatment options.

Types of Hematologic Cancers

Before diving into the role of vaccination in hematologic cancers, it is essential to understand the main categories of hematologic malignancies and the specific challenges they present in terms of treatment.

Leukemia

Leukemia is a cancer that originates in the blood and bone marrow and affects white blood cells. It is classified into two main types: acute and

chronic, further divided by the type of blood cell affected (lymphocytic or myeloid).

Acute Leukemias (such as Acute Lymphocytic Leukemia [ALL] and Acute Myeloid Leukemia [AML]) are characterized by the rapid proliferation of immature blood cells, which often crowd out normal cells and prevent proper immune function.

Chronic Leukemias (including Chronic Lymphocytic Leukemia [CLL] and Chronic Myeloid Leukemia [CML]) develop more slowly, and the leukemic cells tend to remain more differentiated.

Lymphoma

Lymphomas are cancers that arise from lymphocytes, which are white blood cells crucial to the immune system. There are two main types:

Hodgkin Lymphoma (HL): Characterized by the presence of Reed-Sternberg cells, this lymphoma often presents as enlarged lymph nodes.

Non-Hodgkin Lymphoma (NHL): This is a more diverse group of diseases with varying prognoses, and it accounts for a larger percentage of lymphoma cases.

Multiple Myeloma

Multiple myeloma is a cancer of plasma cells, which are responsible for producing antibodies. In this disease, abnormal plasma cells accumulate in the bone marrow, leading to bone damage, immune suppression, and kidney failure.

Myelodysplastic Syndromes (MDS)

MDS refers to a group of disorders caused by poorly developed or dysfunctional blood cells. It often leads to ineffective blood cell production, anemia, and sometimes progresses to leukemia.

Myeloproliferative Disorders

This group of diseases involves the excessive production of blood cells, often causing problems like clotting or bleeding. These include diseases like polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Each of these cancers presents unique challenges in terms of immune system dysfunction, tumor progression, and treatment resistance. The immune system's role in fighting these cancers has driven the development of new immunotherapeutic approaches, including cancer vaccines.

Vaccine-Based Immunotherapy for Hematologic Cancers

Vaccination, traditionally used for preventing infections, has been explored as a potential therapeutic option for cancer treatment. Cancer vaccines aim to stimulate the body's immune system to recognize and destroy cancer cells. In hematologic cancers, these vaccines focus on targeting specific cancer-related antigens

expressed by the malignant cells.
Immunotherapy, which harnesses the body's immune system to fight cancer, has seen remarkable success in the treatment of hematologic cancers, and vaccines are a key component of this strategy. The basic premise of cancer vaccines is to introduce antigens or stimulate the immune system in a way that enhances the body's ability to recognize and destroy cancer cells. This can be achieved through different types of vaccines, such as peptide vaccines, dendritic cell-based vaccines, and viral vector vaccines.

Types of Vaccines for Hematologic Cancers

Peptide-Based Vaccines

Peptide vaccines are designed to stimulate the immune system by presenting short peptides derived from cancer-specific antigens. These peptides can be either naturally occurring or synthetically engineered to match specific cancer-associated proteins. In hematologic cancers, peptides derived from antigens like CD19, MAGE-A3, or Wilms' Tumor 1 (WT1) are often used, as these are overexpressed in various hematologic malignancies.
For example, peptide vaccines targeting WT1 have been investigated in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The

goal is to prime the immune system to recognize and eliminate cells expressing these antigens. These vaccines can be administered alone or in combination with other immunotherapies, such as immune checkpoint inhibitors.

Dendritic Cell Vaccines

Dendritic cells (DCs) are specialized antigen-presenting cells that play a crucial role in initiating immune responses. Dendritic cell vaccines involve isolating these cells from a patient, loading them with tumor antigens, and then reintroducing them into the body to stimulate a strong immune response. This approach has been explored in various hematologic cancers, including leukemia and lymphoma.
In clinical trials, dendritic cell vaccines have shown promising results, particularly in lymphoma and leukemia, where they help activate T-cells to target tumor cells. Dendritic cell vaccines can also be used in combination with other immunotherapies to boost the immune response.

DNA and RNA Vaccines

DNA and RNA vaccines use genetic material to instruct cells to produce tumor antigens, which then trigger an immune response. These vaccines are attractive because they can be rapidly engineered and do not require the isolation and manipulation of patient cells. DNA vaccines

have been tested in various hematologic cancers, such as leukemia, while RNA vaccines have demonstrated potential in the preclinical stage.
In multiple myeloma, for example, DNA vaccines targeting tumor antigens like MAGE-A3 have been tested, showing the potential to induce long-lasting immune responses. Similarly, RNA vaccines targeting specific tumor proteins are being explored as a promising strategy for treating leukemia and lymphoma.

Oncolytic Virus Vaccines

Oncolytic viruses are genetically modified viruses that selectively infect and kill cancer cells while stimulating the immune system. These viruses are engineered to target cancer cells specifically, leading to the destruction of the tumor and the release of cancer-specific antigens, which further activate immune responses.
For hematologic cancers, oncolytic virus vaccines have shown promise in preclinical and early-phase clinical trials. For example, the use of genetically modified herpes simplex virus (HSV) or vesicular stomatitis virus (VSV) has been explored in leukemia and lymphoma. These therapies aim to exploit the cancer cell-specific tropism of the virus to eradicate tumor cells and activate systemic antitumor immunity.

Challenges and Opportunities

While the development of innovative vaccines

for hematologic cancers is a promising area of research, several challenges must be overcome before these therapies can become mainstream treatments.

Tumor Heterogeneity

One of the biggest challenges in hematologic cancers is the heterogeneity of the tumor. Cancer cells can vary greatly between individuals and even within the same patient over time. This diversity means that the immune system may not recognize all cancer cells as foreign, leading to treatment resistance and relapse. Tailoring vaccines to account for this heterogeneity and improving their ability to target a wide range of cancer cells is a major area of ongoing research.

Immunosuppression in Hematologic Malignancies

Hematologic cancers, especially leukemia and multiple myeloma, often cause immune suppression, making it difficult for the body to mount an effective immune response. Many patients with hematologic cancers have a compromised immune system due to the disease itself or the effects of chemotherapy and radiation. Overcoming this immunosuppressive environment is crucial for the success of cancer vaccines.

Combination Therapies

Combining cancer vaccines with other therapies, such as immune checkpoint inhibitors, monoclonal antibodies, or chemotherapy, holds great potential for enhancing the efficacy of vaccines. By reducing the tumor's ability to evade the immune system, combination therapies can improve the immune system's response to cancer vaccines. However, optimizing these combinations and determining the best treatment protocols remain important areas of investigation.

Personalized Vaccines

Personalizing vaccines to target specific mutations or antigens unique to an individual's cancer holds the potential to improve outcomes. This approach requires sophisticated techniques for identifying tumor-specific antigens and tailoring vaccines accordingly. While personalized vaccines show great promise, the technology to design and produce them is still in the early stages.

Conclusion

Innovative vaccination strategies represent a promising new frontier in the treatment of hematologic cancers. While challenges such as tumor heterogeneity and immune suppression remain, ongoing research into peptide-based vaccines, dendritic cell vaccines, DNA and RNA vaccines, and oncolytic virus vaccines is paving the way for new and potentially transformative therapies. As our understanding of the immune

system's role in cancer continues to evolve, the integration of vaccination into standard treatment protocols may provide patients with more effective and less toxic options for fighting hematologic cancers. The future of cancer immunotherapy, including vaccination, looks bright, and it holds the potential to significantly improve the prognosis for patients with hematologic malignancies.

REFERENCES

1. Ahmed KK, Geary SM, Salem AK. Applying biodegradable particles to enhance cancer vaccine efficacy. Immunol Res. 2014;59(1-3):220-8.
2. Al-Hawary SIS, Jasim SA, Hjazi A, Oghenemaro EF, Kaur I, Kumar A, et al. Nucleic acid-based vaccine for ovarian cancer cells; bench to bedside. Cell Biochem Funct. 2024;42(2):e3978.
3. Alqarni A, Jasim SA, Altalbawy FMA, Kaur H, Kaur I, Rodriguez-Benites C, et al. Challenges and opportunities for cancer stem cell-targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell-dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes. J Biochem Mol Toxicol. 2024;38(6):e23719.
4. Altinoz MA, Ozpinar A, Ozpinar A, Hacker E, Elmaci İ. Could hepatitis B vaccine act as an adjuvant to lower risk and relapses of cancer? Clin Exp Pharmacol Physiol. 2019;46(8):694-704.
5. Amedei A, Niccolai E, Prisco D. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum Vaccin Immunother. 2014;10(11):3354-68.
6. Ammi R, De Waele J, Willemen Y, Van Brussel I, Schrijvers DM, Lion E, et al. Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. Pharmacol Ther.

2015;146:120-31.
7. Arab A, Yazdian-Robati R, Behravan J. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development. Arch Immunol Ther Exp (Warsz). 2020;68(1):2.
8. Arriola E, Ottensmeier C. TG4010: a vaccine with a therapeutic role in cancer. Immunotherapy. 2016;8(5):511-9.
9. Ashraf MU, Jeong Y, Roh SE, Bae YS. Transendothelial migration (TEM) of in vitro generated dendritic cell vaccine in cancer immunotherapy. Arch Pharm Res. 2019;42(7):582-90.
10. Banday AH, Jeelani S, Hruby VJ. Cancer vaccine adjuvants--recent clinical progress and future perspectives. Immunopharmacol Immunotoxicol. 2015;37(1):1-11.
11. Barrière J, Carles M, Audigier-Valette C, Re D, Adjtoutah Z, Seitz-Polski B, et al. Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article. Eur J Cancer. 2022;162:182-93.
12. Baxevanis CN, Fortis SP, Ardavanis A, Perez SA. Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design. Cancers (Basel). 2020;12.(10)
13. Beckwith DM, Cudic M. Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design. Semin Immunol. 2020;47:101389.
14. Behzadi E, Halabian R, Hosseini HM,

Fooladi AAI. Bacterial toxin's DNA vaccine serves as a strategy for the treatment of cancer, infectious and autoimmune diseases. Microb Pathog. 2016;100:184-94.
15. Berzofsky JA, Terabe M, Trepel JB, Pastan I, Stroncek DF, Morris JC, et al. Cancer vaccine strategies: translation from mice to human clinical trials. Cancer Immunol Immunother. 2018;67(12):1863-9.
16. Bin Umair M, Akusa FN, Kashif H, Seerat EF, Butt F, Azhar M, et al. Viruses as tools in gene therapy, vaccine development, and cancer treatment. Arch Virol. 2022;167(6):1387-404.
17. Bolhassani A, Javanzad S, Saleh T, Hashemi M, Aghasadeghi MR, Sadat SM. Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases. Hum Vaccin Immunother. 2014;10(2):321-32.
18. Bolivar AM, Duzagac F, Sinha KM, Vilar E. Advances in vaccine development for cancer prevention and treatment in Lynch Syndrome. Mol Aspects Med. 2023;93:101204.
19. Bouzid R, Peppelenbosch M, Buschow SI. Opportunities for Conventional and in Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review. Cancers (Basel). 2020;12.(5)
20. Bowen CM, Sinha KM, Vilar E. Current Trends in Vaccine Development for Hereditary Colorectal Cancer Syndromes. Clin Colon Rectal Surg. 2024;37(3):146-56.

21. Bowen WS, Svrivastava AK, Batra L, Barsoumian H, Shirwan H. Current challenges for cancer vaccine adjuvant development. Expert Rev Vaccines. 2018;17(3):207-15.
22. Brauns T, Leblanc P, Gelfand JA, Poznanski M. Could mycobacterial Hsp70-containing fusion protein lead the way to an affordable therapeutic cancer vaccine? Expert Rev Vaccines. 2015;14(3):435-46.
23. Brezar V, Godot V, Cheng L, Su L, Lévy Y, Seddiki N. T-Regulatory Cells and Vaccination "Pay Attention and Do Not Neglect Them": Lessons from HIV and Cancer Vaccine Trials. Vaccines (Basel). 2016;4.(3)
24. Bright RK. Preclinical support for tumor protein D52 as a cancer vaccine antigen. Hum Vaccin Immunother. 2023;19(3):2273699.
25. Brugiapaglia S, Spagnolo F, Intonti S, Novelli F, Curcio C. Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality? Cells. 2024;13.(18)
26. Bryan JT, Buckland B, Hammond J, Jansen KU. Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine. Curr Opin Chem Biol. 2016;32:34-47.
27. Buonaguro L, Tagliamonte M. Selecting Target Antigens for Cancer Vaccine Development. Vaccines (Basel). 2020;8.(4)
28. Buonaguro L, Tagliamonte M. Peptide-based vaccine for cancer therapies. Front

Immunol. 2023;14:1210044.
29. Burke EE, Kodumudi K, Ramamoorthi G, Czerniecki BJ. Vaccine Therapies for Breast Cancer. Surg Oncol Clin N Am. 2019;28(3):353-67.
30. Butow P, Shaw J, Bartley N, Milch V, Sathiaraj R, Turnbull S, et al. Vaccine hesitancy in cancer patients: A rapid review. Patient Educ Couns. 2023;111:107680.
31. Butterfield LH. Lessons learned from cancer vaccine trials and target antigen choice. Cancer Immunol Immunother. 2016;65(7):805-12.
32. Cachay ER, Mathews WC. Use of human papillomavirus vaccine in HIV-infected men for the prevention of anal dysplasia and cancer. AIDS Rev. 2014;16(2):90-100.
33. Cai J, Wang H, Wang D, Li Y. Improving Cancer Vaccine Efficiency by Nanomedicine. Adv Biosyst. 2019;3(3):e1800287.
34. Cai X, Xu L. Human Papillomavirus-Related Cancer Vaccine Strategies. Vaccines (Basel). 2024;12.(11)
35. Casper C, Corey L, Cohen JI, Damania B, Gershon AA, Kaslow DC, et al. KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine. NPJ Vaccines. 2022;7(1):108.
36. Catanzaro E, Feron O, Skirtach AG, Krysko DV. Immunogenic Cell Death and Role of Nanomaterials Serving as Therapeutic Vaccine for Personalized Cancer Immunotherapy. Front Immunol. 2022;13:925290.

37. Chakraborty C, Sharma AR, Bhattacharya M, Lee SS. From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape. Front Immunol. 2021;12:679344.
38. Chamani R, Ranji P, Hadji M, Nahvijou A, Esmati E, Alizadeh AM. Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta-analysis. Eur J Pharmacol. 2018;831:87-93.
39. Chandarana C, Tiwari A. A Review of Clinical Trials of Cancer and Its Treatment as a Vaccine. Rev Recent Clin Trials. 2024;19(1):7-33.
40. Chen C, Xu Y, Meng H, Bao H, Hu Y, Li C, et al. Nano-Oncologic Vaccine for Boosting Cancer Immunotherapy: The Horizons in Cancer Treatment. Nanomaterials (Basel). 2025;15.(2)
41. Chen M, Zhou Y, Fu Y, Wang Q, Wu C, Pan X, et al. Biomaterials-assisted cancer vaccine delivery: preclinical landscape, challenges, and opportunities. Expert Opin Drug Deliv. 2024;21(7):1143-54.
42. Chen R, Fulton KM, Twine SM, Li J. IDENTIFICATION OF MHC PEPTIDES USING MASS SPECTROMETRY FOR NEOANTIGEN DISCOVERY AND CANCER VACCINE DEVELOPMENT. Mass Spectrom Rev. 2021;40(2):110-25.
43. Cheng EM, Tsarovsky NW, Sondel PM, Rakhmilevich AL. Interleukin-12 as an in situ cancer vaccine component: a review. Cancer Immunol Immunother. 2022;71(9):2057-65.

44. Cheng L, Wang R, Yan J. A review of urinary HPV testing for cervical cancer management and HPV vaccine surveillance: rationale, strategies, and limitations. Eur J Clin Microbiol Infect Dis. 2024;43(12):2247-58.
45. Cherryholmes GA, Stanton SE, Disis ML. Current methods of epitope identification for cancer vaccine design. Vaccine. 2015;33(51):7408-14.
46. Chesson CB, Zloza A. Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer. Nanomedicine (Lond). 2017;12(23):2693-706.
47. Circelli L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L. Systems Biology Approach for Cancer Vaccine Development and Evaluation. Vaccines (Basel). 2015;3(3):544-55.
48. Clifton GT, Gall V, Peoples GE, Mittendorf EA. Clinical Development of the E75 Vaccine in Breast Cancer. Breast Care (Basel). 2016;11(2):116-21.
49. Clifton GT, Kohrt HE, Peoples GE. Critical issues in cancer vaccine trial design. Vaccine. 2015;33(51):7386-92.
50. Connors JM, Iba T. Vaccine-induced immune thrombotic thrombocytopenia and patients with cancer. Thromb Res. 2022;213 Suppl 1:S77-s83.
51. Crombet Ramos T, Rodríguez PC, Neninger Vinageras E, Garcia Verdecia B, Lage Davila

A. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer. Expert Rev Vaccines. 2015;14(10):1303-11.
52. Dailey GP, Crosby EJ, Hartman ZC. Cancer vaccine strategies using self-replicating RNA viral platforms. Cancer Gene Ther. 2023;30(6):794-802.
53. Danaeifar M, Negahdari B, Eslam HM, Zare H, Ghanaat M, Koushali SS, et al. Polymeric nanoparticles for DNA vaccine-based cancer immunotherapy: a review. Biotechnol Lett. 2023;45(9):1053-72.
54. Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021;18(5):313-9.
55. Devaraja K, Singh M, Sharan K, Aggarwal S. Coley's Toxin to First Approved Therapeutic Vaccine-A Brief Historical Account in the Progression of Immunobiology-Based Cancer Treatment. Biomedicines. 2024;12.(12)
56. Dhanushkumar T, M ES, Selvam PK, Rambabu M, Dasegowda KR, Vasudevan K, et al. Advancements and hurdles in the development of a vaccine for triple-negative breast cancer: A comprehensive review of multi-omics and immunomics strategies. Life Sci. 2024;337:122360.
57. Di Bonito P, Accardi L, Galati L, Ferrantelli F, Federico M. Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic

HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes. Cancers (Basel). 2019;11.(2)
58. Diana G, Corica C. Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence? Oral Oncol. 2021;115:105168.
59. Ding H, Zhang J, Zhang F, Xu Y, Yu Y, Liang W, et al. Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer. Front Oncol. 2022;12:990877.
60. Duan LJ, Wang Q, Zhang C, Yang DX, Zhang XY. Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy. Front Immunol. 2022;13:923647.
61. Ede NJ, Good AJ, Tobias J, Garner-Spitzer E, Zielinski CC, Wiedermann U. Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers. Front Oncol. 2022;12:939356.
62. Fan C, Qu H, Wang X, Sobhani N, Wang L, Liu S, et al. Cancer/testis antigens: from serology to mRNA cancer vaccine. Semin Cancer Biol. 2021;76:218-31.
63. Fantini M, Tsang KY, Arlen PM. Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells. Expert Rev Vaccines. 2024;23(1):812-29.
64. Feng C, Li Y, Ferdows BE, Patel DN, Ouyang

J, Tang Z, et al. Emerging vaccine nanotechnology: From defense against infection to sniping cancer. Acta Pharm Sin B. 2022;12(5):2206-23.
65. Feng C, Tan P, Nie G, Zhu M. Biomimetic and bioinspired nano-platforms for cancer vaccine development. Exploration (Beijing). 2023;3(3):20210263.
66. Ford ME, Cannady K, Nahhas GJ, Knight KD, Chavis C, Crawford B, et al. Assessing an intervention to increase knowledge related to cervical cancer and the HPV vaccine. Adv Cancer Res. 2020;146:115-37.
67. Freeman-Keller M, Goldman J, Gray J. Vaccine immunotherapy in lung cancer: Clinical experience and future directions. Pharmacol Ther. 2015;153:1-9.
68. Gabai VL, Shifrin VI. Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy. Int Rev Immunol. 2014;33(5):375-82.
69. Gajdosik Z. Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer. Drugs Today (Barc). 2014;50(4):301-7.
70. Galati D, Zanotta S, Bocchino M, De Filippi R, Pinto A. The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies? Cancer Immunol Immunother. 2021;70(7):1797-809.
71. Gao T, Cen Q, Lei H. A review on

development of MUC1-based cancer vaccine. Biomed Pharmacother. 2020;132:110888.
72. García-Pardo M, Gorria T, Malenica I, Corgnac S, Teixidó C, Mezquita L. Vaccine Therapy in Non-Small Cell Lung Cancer. Vaccines (Basel). 2022;10.(5)
73. Garland SM, Brown DR. Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer. Expert Opin Biol Ther. 2014;14(4):527-34.
74. Giudice GC, Sonpavde GP. Vaccine approaches to treat urothelial cancer. Hum Vaccin Immunother. 2024;20(1):2379086.
75. Glybochko PV, Fisenko VP. IMMUNOTHERAPY OF BLADDER CANCER. BCG VACCINE: PRINCIPLES OF ACTION, EFFICACY AND SAFETY. Eksp Klin Farmakol. 2016;79(10):34-43.
76. González FE, Gleisner A, Falcón-Beas F, Osorio F, López MN, Salazar-Onfray F. Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum Vaccin Immunother. 2014;10(11):3261-9.
77. Grant M, Ni Lee L, Chinnakannan S, Tong O, Kwok J, Cianci N, et al. Unlocking cancer vaccine potential: What are the key factors? Hum Vaccin Immunother. 2024;20(1):2331486.
78. Gu Q, Qi A, Wang N, Zhou Z, Zhou X. Unlocking Immunity: Innovative prostate cancer vaccine strategies. Int Immunopharmacol. 2024;142(Pt A):113137.
79. Gugulothu KN, Anvesh Sai P, Suraparaju S,

Karuturi SP, Pendli G, Kamma RB, et al. WT1 Cancer Vaccine in Advanced Pancreatic Cancer: A Systematic Review. Cureus. 2024;16(3):e56934.
80. Guo M, Dou J. Advances and perspectives of colorectal cancer stem cell vaccine. Biomed Pharmacother. 2015;76:107-20.
81. Gupta DS, Gupta DS, Abjani NK, Dave Y, Apte K, Kaur G, et al. Vaccine-based therapeutic interventions in lung cancer management: A recent perspective. Med Oncol. 2024;41(11):249.
82. Gupta R, Rady PL, Doan HQ, Tyring SK. Development of a β-HPV vaccine: Updates on an emerging frontier of skin cancer prevention. J Clin Virol. 2020;126:104348.
83. Han HJ, Nwagwu C, Anyim O, Ekweremadu C, Kim S. COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology. Int Immunopharmacol. 2021;90:107247.
84. Han S, Lee SY, Wang WW, Tan YB, Sim RHZ, Cheong R, et al. A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs). Cancers (Basel). 2020;12.(11)
85. He Y, Ding Y, Cao B, Huang Y, Wang X. COVID-19 vaccine development from the perspective of cancer patients. Hum Vaccin Immunother. 2021;17(10):3281-7.
86. Hein KZ, Yao S, Fu S. Wilms' Tumor 1 (WT1): The Vaccine for Cancer. J Immunother Precis Oncol. 2020;3(4):165-71.
87. Hernández AM, Vázquez AM.

Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer. Expert Rev Vaccines. 2015;14(1):9-20.
88. Hong J, Xu XW, Yang J, Zheng J, Dai SM, Zhou J, et al. Knowledge about, attitude and acceptance towards, and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China: A cross-sectional survey. J Integr Med. 2022;20(1):34-44.
89. Hossain F, Kandalai S, Zhou X, Zhang N, Zheng Q. Chemical and Synthetic Biology Approaches for Cancer Vaccine Development. Molecules. 2022;27.(20)
90. Huang QT, Zhong M, Gao YF, Huang LP, Huang Q, Wang W, et al. Can HPV vaccine have other health benefits more than cancer prevention? A systematic review of association between cervical HPV infection and preterm birth. J Clin Virol. 2014;61(3):321-8.
91. Huang X, Zhang G, Tang TY, Gao X, Liang TB. Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Mil Med Res. 2022;9(1):53.
92. Hundal J, Miller CA, Griffith M, Griffith OL, Walker J, Kiwala S, et al. Cancer Immunogenomics: Computational Neoantigen Identification and Vaccine Design. Cold Spring Harb Symp Quant Biol. 2016;81:105-11.
93. Ibeanu GC, Rowaiye AB, Okoli JC, Eze DU. Microbiome Differences in Colorectal Cancer Patients and Healthy Individuals: Implications for

Vaccine Antigen Discovery. Immunotargets Ther. 2024;13:749-74.
94. Ibrahim M, Kim P, Marawar R, Avgerinos KI. Bacillus Calmette-Guerin (BCG) Vaccine Impact on Dementia Risk in Bladder Cancer Patients: A Systematic Review and Meta-Analysis. J Prev Alzheimers Dis. 2024;11(5):1355-62.
95. Ikewaki N, Dedeepiya VD, Raghavan K, Rao KS, Vaddi S, Osawa H, et al. β-glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B-VACCIEN) in specific immunocompromised populations (Review). Oncol Rep. 2022;47.(1)
96. Jahan S, Mukherjee S, Ali S, Bhardwaj U, Choudhary RK, Balakrishnan S, et al. Pioneer Role of Extracellular Vesicles as Modulators of Cancer Initiation in Progression, Drug Therapy, and Vaccine Prospects. Cells. 2022;11.(3)
97. Jeon D, Hill E, McNeel DG. Toll-like receptor agonists as cancer vaccine adjuvants. Hum Vaccin Immunother. 2024;20(1):2297453.
98. John-Akinola YO, Ndikom CM, Oluwasanu MM, Adebisi T, Odukoya O. Cervical Cancer and Human Papillomavirus Vaccine Knowledge, Utilisation, Prevention Educational Interventions and Policy Response in Nigeria: A Scoping Review. Cancer Control. 2022;29:10732748221130180.
99. Jucht A, Dumont S, Pooley C, Gonzalez Castro LN. Cancer vaccine strategies for the treatment of diffusely infiltrating gliomas. Ther Adv Vaccines Immunother.

2023;11:25151355231206163.
100. Kaczmarek M, Poznańska J, Fechner F, Michalska N, Paszkowska S, Napierała A, et al. Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review. Cells. 2023;12.(17)
101. Kamolratanakul S, Pitisuttithum P. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines (Basel). 2021;9.(12)
102. Kardani K, Bolhassani A, Namvar A. An overview of in silico vaccine design against different pathogens and cancer. Expert Rev Vaccines. 2020;19(8):699-726.
103. Karim AM, Eun Kwon J, Ali T, Jang J, Ullah I, Lee YG, et al. Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. Biochem Pharmacol. 2023;212:115545.
104. Kaumaya PT. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncol. 2020;16(23):1767-91.
105. Kaur A, Baldwin J, Brar D, Salunke DB, Petrovsky N. Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics. Curr Opin Chem Biol. 2022;70:102172.
106. Kazi B, Talukdar Z, Schriefer J. Quality Improvement Interventions to Enhance Vaccine Uptake in Cancer Patients: A Systematic Review. J Healthc Qual. 2024;46(2):81-94.

107. Kelly M, McNeel D, Fisch P, Malkovsky M. Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies. Immunol Lett. 2018;193:1-10.
108. Kelly-Hanku A, Newland J, Aggleton P, Ase S, Aeno H, Fiya V, et al. HPV vaccination in Papua New Guinea to prevent cervical cancer in women: Gender, sexual morality, outsiders and the de-feminization of the HPV vaccine. Papillomavirus Res. 2019;8:100171.
109. Kenoosh HA, Pallathadka H, Hjazi A, Al-Dhalimy AMB, Zearah SA, Ghildiyal P, et al. Recent advances in mRNA-based vaccine for cancer therapy; bench to bedside. Cell Biochem Funct. 2024;42(2):e3954.
110. Kessler AL, Bruno MJ, Buschow SI. The Potential of Soluble Human Leukocyte Antigen Molecules for Early Cancer Detection and Therapeutic Vaccine Design. Vaccines (Basel). 2020;8.(4)
111. Khatami M. Deceptology in cancer and vaccine sciences: Seeds of immune destruction-mini electric shocks in mitochondria: Neuroplasticity-electrobiology of response profiles and increased induced diseases in four generations - A hypothesis. Clin Transl Med. 2020;10(8):e215.
112. Kim H, Griffith TS, Panyam J. Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine. J Pharmacol Exp Ther.

2019;370(3):715-24.
113. Kirner A, Mayer-Mokler A, Reinhardt C. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer. Hum Vaccin Immunother. 2014;10(11):3179-89.
114. Kissick HT. Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens as Vaccine Targets for Cancer. Cold Spring Harb Perspect Biol. 2018;10.(11)
115. Koido S, Okamoto M, Kobayashi M, Shimodaira S, Sugiyama H. Significance of Wilms' tumor 1 antigen as a cancer vaccine for pancreatic cancer. Discov Med. 2017;24(130):41-9.
116. Kondapuram SK, Ramachandran HK, Arya H, Coumar MS. Targeting survivin for cancer therapy: Strategies, small molecule inhibitors and vaccine based therapeutics in development. Life Sci. 2023;335:122260.
117. Koti M, Morales A, Graham CH, Siemens DR. BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy. J Immunother Cancer. 2020;8.(2)
118. Kumar A, Dixit S, Srinivasan K, M D, Vincent P. Personalized cancer vaccine design using AI-powered technologies. Front Immunol. 2024;15:1357217.
119. Kumar S, Malviya R, Uniyal P. Vaccine for Targeted Therapy of Lung Cancer: Advances and Developments. Curr Drug Targets. 2024;25(8):526-9.

120. Lancaster EM, Jablons D, Kratz JR. Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development. Genet Test Mol Biomarkers. 2020;24(2):59-66.
121. Lane DL, Neelapu SS, Xu G, Weaver O. COVID-19 Vaccine-Related Axillary and Cervical Lymphadenopathy in Patients with Current or Prior Breast Cancer and Other Malignancies: Cross-Sectional Imaging Findings on MRI, CT, and PET-CT. Korean J Radiol. 2021;22(12):1938-45.
122. Lebossé F, Zoulim F. [Hepatitis B vaccine and liver cancer]. Bull Cancer. 2021;108(1):90-101.
123. Lei L, Huang D, Gao H, He B, Cao J, Peppas NA. Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy. Sci Adv. 2022;8(47):eadc8738.
124. Li R, Chibbar R, Xiang J. Novel EXO-T vaccine using polyclonal CD4(+) T cells armed with HER2-specific exosomes for HER2-positive breast cancer. Onco Targets Ther. 2018;11:7089-93.
125. Li Y, Wang M, Peng X, Yang Y, Chen Q, Liu J, et al. mRNA vaccine in cancer therapy: Current advance and future outlook. Clin Transl Med. 2023;13(8):e1384.
126. Liang J, Zhao X. Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development. Cancer Biol Med. 2021;18(2):352-71.
127. Lim J, Lee SA, Khil EK, Byeon SJ, Kang

HJ, Choi JA. COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: Case series with a review of literature. Semin Oncol. 2021;48(4-6):283-91.
128. Lim YT. Vaccine adjuvant materials for cancer immunotherapy and control of infectious disease. Clin Exp Vaccine Res. 2015;4(1):54-8.
129. Liu N, Xiao X, Zhang Z, Mao C, Wan M, Shen J. Advances in Cancer Vaccine Research. ACS Biomater Sci Eng. 2023;9(11):5999-6023.
130. Liu W, Tang H, Li L, Wang X, Yu Z, Li J. Peptide-based therapeutic cancer vaccine: Current trends in clinical application. Cell Prolif. 2021;54(5):e13025.
131. Luchner M, Reinke S, Milicic A. TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases. Pharmaceutics. 2021;13.(2)
132. Lundstrom K. Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer. Vaccines (Basel). 2021;9.(10)
133. Luo W, Yang G, Luo W, Cao Z, Liu Y, Qiu J, et al. Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory. Cancer Cell Int. 2020;20:66.
134. Lybaert L, Vermaelen K, De Geest BG, Nuhn L. Immunoengineering through cancer vaccines - A personalized and multi-step vaccine approach towards precise cancer immunity. J Control Release. 2018;289:125-45.

135. Malla R, Srilatha M, Muppala V, Farran B, Chauhan VS, Nagaraju GP. Neoantigens and cancer-testis antigens as promising vaccine candidates for triple-negative breast cancer: Delivery strategies and clinical trials. J Control Release. 2024;370:707-20.
136. Manoutcharian K, Gevorkian G. Are we getting closer to a successful neoantigen cancer vaccine? Mol Aspects Med. 2024;96:101254.
137. Marriott M, Post B, Chablani L. A comparison of cancer vaccine adjuvants in clinical trials. Cancer Treat Res Commun. 2023;34:100667.
138. Martin-Lluesma S, Graciotti M, Grimm AJ, Boudousquié C, Chiang CL, Kandalaft LE. Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer? Curr Opin Biotechnol. 2020;65:190-6.
139. Matsui H, Hazama S, Shindo Y, Nagano H. Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies. Expert Rev Anticancer Ther. 2018;18(12):1205-17.
140. Mazzio E, Barnes A, Badisa R, Council S, Soliman KFA. Plants against cancer: the immune-boosting herbal microbiome: not of the plant, but in the plant. Basic concepts, introduction, and future resource for vaccine adjuvant discovery. Front Oncol. 2023;13:1180084.
141. McCarthy PM, Clifton GT, Vreeland TJ, Adams AM, O'Shea AE, Peoples GE. AE37: a HER2-

targeted vaccine for the prevention of breast cancer recurrence. Expert Opin Investig Drugs. 2021;30(1):5-11.
142. McCarthy PM, Valdera FA, Smolinsky TR, Adams AM, O'Shea AE, Thomas KK, et al. Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials. Front Immunol. 2023;14:1090533.
143. Meena SS, Kosgei BK, Soko GF, Tingjun C, Chambuso R, Mwaiselage J, et al. Developing anti-TDE vaccine for sensitizing cancer cells to treatment and metastasis control. NPJ Vaccines. 2025;10(1):18.
144. Mensah FA, Mehta MR, Lewis JS, Jr., Lockhart AC. The Human Papillomavirus Vaccine: Current Perspective and Future Role in Prevention and Treatment of Anal Intraepithelial Neoplasia and Anal Cancer. Oncologist. 2016;21(4):453-60.
145. Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20(1):41.
146. Miltz A, Price H, Shahmanesh M, Copas A, Gilson R. Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure. PLoS One. 2014;9(3):e90348.
147. Mody N, Dubey S, Sharma R, Agrawal U, Vyas SP. Dendritic cell-based vaccine research against cancer. Expert Rev Clin Immunol. 2015;11(2):213-32.
148. Mohsin SF. Vaccine a promising

immunotherapy option for head and neck cancer patients. Pak J Med Sci. 2024;40(7):1578-83.
149. Morales CG, Jimenez NR, Herbst-Kralovetz MM, Lee NR. Novel Vaccine Strategies and Factors to Consider in Addressing Health Disparities of HPV Infection and Cervical Cancer Development among Native American Women. Med Sci (Basel). 2022;10.(3)
150. Morera-Díaz Y, Gavilondo JV, Bequet-Romero M, Sánchez Ramírez J, Hernández-Bernal F, Selman-Housein KH, et al. Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside. Semin Oncol. 2018;45(1-2):68-74.
151. Morse MA, Gwin WR, 3rd, Mitchell DA. Vaccine Therapies for Cancer: Then and Now. Target Oncol. 2021;16(2):121-52.
152. Mougel A, Terme M, Tanchot C. Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade. Front Immunol. 2019;10:467.
153. Nahas MR, Rosenblatt J, Lazarus HM, Avigan D. Anti-cancer vaccine therapy for hematologic malignancies: An evolving era. Blood Rev. 2018;32(4):312-25.
154. Nakahara Y, Kouro T, Igarashi Y, Kawahara M, Sasada T. Prospects for a personalized peptide vaccine against lung cancer. Expert Rev Vaccines. 2019;18(7):703-9.
155. Näsman A, Du J, Dalianis T. A global

epidemic increase of an HPV-induced tonsil and tongue base cancer - potential benefit from a pan-gender use of HPV vaccine. J Intern Med. 2020;287(2):134-52.
156. Neek M, Kim TI, Wang SW. Protein-based nanoparticles in cancer vaccine development. Nanomedicine. 2019;15(1):164-74.
157. Nikfarjam S, Rezaie J, Kashanchi F, Jafari R. Dexosomes as a cell-free vaccine for cancer immunotherapy. J Exp Clin Cancer Res. 2020;39(1):258.
158. Nordin ML, Azemi AK, Nordin AH, Nabgan W, Ng PY, Yusoff K, et al. Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects. Pharmaceuticals (Basel). 2023;16.(7)
159. O'Neill AM, Dwyer R. Primary prevention of cervical cancer in women: Human papillomavirus vaccine. Eur J Obstet Gynecol Reprod Biol. 2023;281:29-31.
160. Obara W, Kanehira M, Katagiri T, Kato R, Kato Y, Takata R. Present status and future perspective of peptide-based vaccine therapy for urological cancer. Cancer Sci. 2018;109(3):550-9.
161. Ogasawara M. Wilms' tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives. Hum Vaccin Immunother. 2024;20(1):2296735.
162. Okamoto M, Kobayashi M, Yonemitsu Y, Koido S, Homma S. Dendritic cell-based vaccine for pancreatic cancer in Japan. World J Gastrointest Pharmacol Ther. 2016;7(1):133-8.

163. Olatunji G, Kokori E, Yusuf IA, Akinmoju O, Isarinade T, Komolafe R, et al. AE37 HER2-targeted vaccine in the prevention of breast cancer recurrence: A mini narrative review of current evidence. Medicine (Baltimore). 2023;102(52):e36793.
164. Oliveres H, Caglevic C, Passiglia F, Taverna S, Smits E, Rolfo C. Vaccine and immune cell therapy in non-small cell lung cancer. J Thorac Dis. 2018;10(Suppl 13):S1602-s14.
165. Pampeno C, Opp S, Hurtado A, Meruelo D. Sindbis Virus Vaccine Platform: A Promising Oncolytic Virus-Mediated Approach for Ovarian Cancer Treatment. Int J Mol Sci. 2024;25.(5)
166. Pan D, Liu J, Huang X, Wang S, Kuerban K, Yan Y, et al. Challenges and New Directions in Therapeutic Cancer Vaccine Development. Vaccines (Basel). 2024;12.(12)
167. Pan RY, Chung WH, Chu MT, Chen SJ, Chen HC, Zheng L, et al. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. J Immunol Res. 2018;2018:4325874.
168. Pappas G, Saloustros E, Boutis A, Tsoukalas N, Nikolaou M, Christopoulou A, et al. Vaccine third dose and cancer patients: necessity or luxury? ESMO Open. 2021;6(6):100306.
169. Pathak P, Pajai S, Kesharwani H. A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer. Cureus. 2022;14(9):e28710.
170. Pender A, Jones RL, Pollack S. Optimising Cancer Vaccine Design in Sarcoma. Cancers (Basel).

2018;11.(1)
171. Petrie K, Wells A, Eckert LO. Human Papillomavirus Vaccine: The Cancer Prevention Moonshot. Obstet Gynecol Clin North Am. 2023;50(2):339-48.
172. Petrizzo A, Tagliamonte M, Tornesello M, Buonaguro FM, Buonaguro L. Systems vaccinology for cancer vaccine development. Expert Rev Vaccines. 2014;13(6):711-9.
173. Prabani KIP, Weerasekara I, Damayanthi H. COVID-19 vaccine acceptance and hesitancy among patients with cancer: a systematic review and meta-analysis. Public Health. 2022;212:66-75.
174. Prawiningrum AF, Paramita RI, Panigoro SS. Immunoinformatics Approach for Epitope-Based Vaccine Design: Key Steps for Breast Cancer Vaccine. Diagnostics (Basel). 2022;12.(12)
175. Qiao Y, Agboola OS, Hu X, Wu Y, Lei L. Tumorigenic and Immunogenic Properties of Induced Pluripotent Stem Cells: a Promising Cancer Vaccine. Stem Cell Rev Rep. 2020;16(6):1049-61.
176. Quinn M, Erkes DA, Snyder CM. Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector. Immunotherapy. 2016;8(2):211-21.
177. Quintella CM, Quintella HM, Rohweder M, Quintella GM. Advances in patent applications related to cancer vaccine using CpG-ODN and OX40 association. Expert Opin Ther Pat.

2020;30(4):287-301.
178. Rahman M, Sahoo A, Almalki WH, Salman Almujri S, Aodah A, Alnofei AA, et al. Three-dimensional cell culture: Future scope in cancer vaccine development. Drug Discov Today. 2024;29(9):104114.
179. Rausch S, Schwentner C, Stenzl A, Bedke J. mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Hum Vaccin Immunother. 2014;10(11):3146-52.
180. Ren S, Zhang Z, Li M, Wang D, Guo R, Fang X, et al. Cancer testis antigen subfamilies: Attractive targets for therapeutic vaccine (Review). Int J Oncol. 2023;62.(6)
181. Renduchintala K, Arevalo M, Fonseca G, Haver MK, Gwede CK, Pabbathi S, et al. Vaccination uptake among post-treatment cancer survivors: A multi-vaccine scoping review. Vaccine. 2024;42(22):125995.
182. Rezaei T, Davoudian E, Khalili S, Amini M, Hejazi M, de la Guardia M, et al. Strategies in DNA vaccine for melanoma cancer. Pigment Cell Melanoma Res. 2021;34(5):869-91.
183. Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, et al. The Human Vaccines Project: A roadmap for cancer vaccine development. Sci Transl Med. 2016;8(334):334ps9.
184. Ruzzi F, Riccardo F, Conti L, Tarone L, Semprini MS, Bolli E, et al. Cancer vaccines: Target antigens, vaccine platforms and preclinical

models. Mol Aspects Med. 2025;101:101324.
185. Saadeldin MK, Abdel-Aziz AK, Abdellatif A. Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis. Med Hypotheses. 2021;146:110365.
186. Saavedra D, Crombet T. CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. Front Immunol. 2017;8:269.
187. Sadeghi MS, Sangrizeh FH, Jahani N, Abedin MS, Chaleshgari S, Ardakan AK, et al. Graphene oxide nanoarchitectures in cancer therapy: Drug and gene delivery, phototherapy, immunotherapy, and vaccine development. Environ Res. 2023;237(Pt 2):117027.
188. Sadeghi Najafabadi SA, Bolhassani A, Aghasadeghi MR. Tumor cell-based vaccine: an effective strategy for eradication of cancer cells. Immunotherapy. 2022;14(8):639-54.
189. Saeed Y, Zhong R, Sun Z. Advances in traditional herbal formulation based nano-vaccine for cancer immunotherapy: Unraveling the enigma of complex tumor environment and multidrug resistance. Int Immunopharmacol. 2024;132:111948.
190. Sasada T, Yamada A, Noguchi M, Itoh K. Personalized peptide vaccine for treatment of advanced cancer. Curr Med Chem. 2014;21(21):2332-45.
191. Sayour EJ, Mendez-Gomez HR, Mitchell DA. Cancer Vaccine Immunotherapy with RNA-Loaded

Liposomes. Int J Mol Sci. 2018;19.(10)
192. Schneble E, Clifton GT, Hale DF, Peoples GE. Peptide-Based Cancer Vaccine Strategies and Clinical Results. Methods Mol Biol. 2016;1403:797-817.
193. Schneble EJ, Berry JS, Trappey FA, Clifton GT, Ponniah S, Mittendorf E, et al. The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519-31.
194. Seya T, Shime H, Takeda Y, Tatematsu M, Takashima K, Matsumoto M. Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity. Cancer Sci. 2015;106(12):1659-68.
195. Shahvali S, Rahiman N, Jaafari MR, Arabi L. Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy. Drug Deliv Transl Res. 2023;13(7):2041-56.
196. Shanmugaraj B, Priya LB, Mahalakshmi B, Subbiah S, Hu RM, Velmurugan BK, et al. Bacterial and viral vectors as vaccine delivery vehicles for breast cancer therapy. Life Sci. 2020;250:117550.
197. Shaw I, Boafo GF, Ali YS, Liu Y, Mlambo R, Tan S, et al. Advancements and prospects of lipid-based nanoparticles: dual frontiers in cancer treatment and vaccine development. J Microencapsul. 2024;41(3):226-54.

198. Shibata T, Lieblong BJ, Sasagawa T, Nakagawa M. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treat Rev. 2019;78:8-16.
199. Shindo Y, Hazama S, Nagano H. [Cancer Vaccine Focused on Neoantigens]. Gan To Kagaku Ryoho. 2019;46(9):1367-71.
200. Shiro R, Tsunoda I. [HPV vaccinations and cervical cancer in Japan: Flaws in alleged experimental evidence for molecular mimicry and animal models of HPV vaccine-induced "adverse reactions "]. Uirusu. 2024;74(1):17-28.
201. Shirota H, Tross D, Klinman DM. CpG Oligonucleotides as Cancer Vaccine Adjuvants. Vaccines (Basel). 2015;3(2):390-407.
202. Signorelli C, Odone A, Ciorba V, Cella P, Audisio RA, Lombardi A, et al. Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. Epidemiol Infect. 2017;145(10):1962-82.
203. Singh A, Koutsoumpli G, van de Wall S, Daemen T. An alphavirus-based therapeutic cancer vaccine: from design to clinical trial. Cancer Immunol Immunother. 2019;68(5):849-59.
204. Skinner SR, Apter D, De Carvalho N, Harper DM, Konno R, Paavonen J, et al. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. Expert Rev Vaccines. 2016;15(3):367-87.

205. Subbarayan R, Srinivasan D, Balakrishnan R, Kumar A, Usmani SS, Srivastava N. DNA damage response and neoantigens: A favorable target for triple-negative breast cancer immunotherapy and vaccine development. Int Rev Cell Mol Biol. 2024;389:104-52.
206. Sun H, Bu F, Li L, Zhang X, Yan J, Huang T. COVID-19 vaccine response and safety in patients with cancer: An overview of systematic reviews. Front Public Health. 2022;10:1072137.
207. Sunoqrot S, Abdel Gaber SA, Abujaber R, Al-Majawleh M, Talhouni S. Lipid- and Polymer-Based Nanocarrier Platforms for Cancer Vaccine Delivery. ACS Appl Bio Mater. 2024;7(8):4998-5019.
208. Sutherland SIM, Ju X, Horvath LG, Clark GJ. Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer. Front Immunol. 2021;12:641307.
209. Tadros J, Rahnama-Moghadam S. Erythema annulare centrifugum-type eruption in a patient undergoing cancer vaccine immunotherapy. Dermatol Online J. 2018;24.(10)
210. Tagliamento M, Rijavec E, Barletta G, Biello F, Rossi G, Grossi F, et al. CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine. Expert Opin Biol Ther. 2018;18(7):829-35.
211. Tagliamonte M, Cavalluzzo B, Mauriello A, Ragone C, Buonaguro FM, Tornesello ML, et al. Molecular mimicry and cancer vaccine development. Mol Cancer. 2023;22(1):75.

212. Tan T, Deng ST, Wu BH, Yang Q, Wu MW, Wu H, et al. mRNA Vaccine - A New Cancer Treatment Strategy. Curr Cancer Drug Targets. 2023;23(9):669-81.
213. Temizoz B, Kuroda E, Ishii KJ. Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol. 2016;28(7):329-38.
214. Thakur A, Parra DC, Motallebnejad P, Brocchi M, Chen HJ. Exosomes: Small vesicles with big roles in cancer, vaccine development, and therapeutics. Bioact Mater. 2022;10:281-94.
215. Tojjari A, Saeed A, Singh M, Cavalcante L, Sahin IH, Saeed A. A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma. Vaccines (Basel). 2023;11.(8)
216. Torigoe T, Hirohashi Y, Tsukahara T, Kanaseki T, Kochin V, Sato N. [The path to innovative drug development of cancer vaccine: from discovery of tumor antigens to clinical trials]. Nihon Rinsho Meneki Gakkai Kaishi. 2014;37(2):90-5.
217. Tousian B, Khosravi AR, Ghasemi MH, Kadkhodaie M. Biomimetic functionalized metal organic frameworks as multifunctional agents: Paving the way for cancer vaccine advances. Mater Today Bio. 2024;27:101134.
218. Tran S, Truong TH, Narendran A. Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis. Eur J

Cancer. 2021;159:259-74.
219. Tran T, Blanc C, Granier C, Saldmann A, Tanchot C, Tartour E. Therapeutic cancer vaccine: building the future from lessons of the past. Semin Immunopathol. 2019;41(1):69-85.
220. Trigo S, Gonzalez K, Di Matteo L, Ismail A, Elmansy H, Shahrour W, et al. Bacillus Calmette-Guerin vaccine and bladder cancer incidence: Scoping literature review and preliminary analysis. Arch Ital Urol Androl. 2021;93(1):1-8.
221. Tsai HJ. Clinical cancer chemoprevention: From the hepatitis B virus (HBV) vaccine to the human papillomavirus (HPV) vaccine. Taiwan J Obstet Gynecol. 2015;54(2):112-5.
222. Tsentemeidou A, Fyrmpas G, Stavrakas M, Vlachtsis K, Sotiriou E, Poutoglidis A, et al. Human Papillomavirus Vaccine to End Oropharyngeal Cancer. A Systematic Review and Meta-Analysis. Sex Transm Dis. 2021;48(9):700-7.
223. van der Sluis TC, van der Burg SH, Arens R, Melief CJ. New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer. Curr Opin Immunol. 2015;35:9-14.
224. Vermaelen K. Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses. Front Immunol. 2019;10:8.
225. Vielot NA, Brewer NT. Optimizing Cancer Prevention in Adolescents by Improving HPV Vaccine Delivery. N C Med J. 2023;85(1):33-6.
226. Wang L, Pegram MD, Wu JC. Induced

pluripotent stem cells as a novel cancer vaccine. Expert Opin Biol Ther. 2019;19(11):1191-7.
227. Wang M, Cao JX, Liu YS, Xu BL, Li D, Zhang XY, et al. Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis. BMJ Open. 2015;5(4):e006321.
228. Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2020;471:88-102.
229. Wang Y, Liu C, Pang J, Li Z, Zhang J, Dong L. The Extra-Tumoral Vaccine Effects of Apoptotic Bodies in the Advancement of Cancer Treatment. Small. 2025:e2410503.
230. Wei L, Huang K, Han H, Liu RY. Human Papillomavirus Infection in Penile Cancer: Multidimensional Mechanisms and Vaccine Strategies. Int J Mol Sci. 2023;24.(23)
231. Wei L, Xie X, Liu J, Qiao Y, Zhao F, Wu T, et al. Elimination of Cervical Cancer: Challenges Promoting the HPV Vaccine in China. Indian J Gynecol Oncol. 2021;19(3):51.
232. Wei WZ, Jones RF, Juhasz C, Gibson H, Veenstra J. Evolution of animal models in cancer vaccine development. Vaccine. 2015;33(51):7401-7.
233. Wei X, Chen F, Xin K, Wang Q, Yu L, Liu B, et al. Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects. Transl Oncol. 2019;12(5):733-8.

234. Wen R, Umeano AC, Kou Y, Xu J, Farooqi AA. Nanoparticle systems for cancer vaccine. Nanomedicine (Lond). 2019;14(5):627-48.
235. Wilski NA, Snyder CM. From Vaccine Vector to Oncomodulation: Understanding the Complex Interplay between CMV and Cancer. Vaccines (Basel). 2019;7.(3)
236. Wooster AL, Girgis LH, Brazeale H, Anderson TS, Wood LM, Lowe DB. Dendritic cell vaccine therapy for colorectal cancer. Pharmacol Res. 2021;164:105374.
237. Wu M, Wang S, Chen JY, Zhou LJ, Guo ZW, Li YH. Therapeutic cancer vaccine therapy for acute myeloid leukemia. Immunotherapy. 2021;13(10):863-77.
238. Xia W, Wang J, Xu Y, Jiang F, Xu L. L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review. J Thorac Dis. 2014;6(10):1513-20.
239. Yang B, Jeang J, Yang A, Wu TC, Hung CF. DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother. 2014;10(11):3153-64.
240. Yang W, Zhang D, Li Z, Zhang K. Predictors of poor serologic response to COVID-19 vaccine in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2022;172:41-50.
241. Ye T, Li F, Ma G, Wei W. Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors. Adv Drug Deliv Rev. 2021;177:113927.
242. Ye Z, Qian Q, Jin H, Qian Q. Cancer vaccine: learning lessons from immune checkpoint

inhibitors. J Cancer. 2018;9(2):263-8.
243. Yi Y, Yu M, Li W, Zhu D, Mei L, Ou M. Vaccine-like nanomedicine for cancer immunotherapy. J Control Release. 2023;355:760-78.
244. Zdrehus R, Delcea C, Mocan L. Role of Biofunctionalized Nanoparticles in Digestive Cancer Vaccine Development. Pharmaceutics. 2024;16.(3)
245. Zefferino R, Conese M. A Vaccine against Cancer: Can There Be a Possible Strategy to Face the Challenge? Possible Targets and Paradoxical Effects. Vaccines (Basel). 2023;11.(11)
246. Zemp F, Rajwani J, Mahoney DJ. Rhabdoviruses as vaccine platforms for infectious disease and cancer. Biotechnol Genet Eng Rev. 2018;34(1):122-38.
247. Zhang R, Billingsley MM, Mitchell MJ. Biomaterials for vaccine-based cancer immunotherapy. J Control Release. 2018;292:256-76.
248. Zhang X, Yang B, Ni Q, Chen X. Materials engineering strategies for cancer vaccine adjuvant development. Chem Soc Rev. 2023;52(9):2886-910.
249. Zhao J, Liao B, Gong L, Yang H, Li S, Li Y. Knowledge mapping of therapeutic cancer vaccine from 2013 to 2022: A bibliometric and visual analysis. Hum Vaccin Immunother. 2023;19(2):2254262.
250. Zhao X, Zhao R, Nie G. Nanocarriers

based on bacterial membrane materials for cancer vaccine delivery. Nat Protoc. 2022;17(10):2240-74.
251. Zhou W, Lu X, Tian F, Luo Q, Zhou W, Yang S, et al. Vaccine Therapies for Prostate Cancer: Current Status and Future Outlook. Vaccines (Basel). 2024;12.(12)
252. Amiri H, Ghaneiyan M, Farjami P, Mehran H, Mohammadzadeh S, Ghaderi S, et al. AI-Enhanced Virtual Clinics and Telemedicine for Cancer Treatment. Kindle. 2024;4(1):1-207.
253. Farrokhi M, Khouzani SJ, Farrokhi M, Jalayeri H, Faranoush P, Babaei M, et al. Artificial Intelligence and Deep Learning for Screening and Risk Assessment of Cancers. Kindle. 2024;4(1):1-140.
254. Farrokhi M, Taheri F, Adibnia E, Mehrtabar S, Rassaf Z, Tooyserkani SH, et al. The AI Diagnostician: Improving Medical Diagnosis with Artificial Intelligence. Kindle. 2024;4(1):1-219.
255. Farrokhi M, Taheri F, Bayat Z, Damiri M, Farrokhi M, Ghadirzadeh E, et al. Role of Lifestyle Medicine in the Prevention and Treatment of Diseases. Kindle. 2024;4(1):1-219.
256. Farrokhi M, Taheri F, Farrokhi M, Emtiazi N, Talebi M, Akbari A, et al. Human and AI: Collaborative Medicine in the Age of Technology. Kindle. 2024;4(1):1-160.
257. Farrokhi M, Taheri F, Farrokhi M, Heydari Z, Darbani R, Salbi M, et al. Advancements and Innovations in Cancer

Management: A Comprehensive Perspective. Kindle. 2024;4(1):1-161.
258. Farrokhi M, Taheri F, Farrokhi M, Moeini A, Tooyserkani SH, Shahali A, et al. Anti-Aging Strategies to Prevent Diseases: Promoting Longevity and Optimal Health. Kindle. 2024;4(1):1-194.
259. Farrokhi M, Taheri F, Farrokhi M, Tosi YEK, Ghadirzadeh E, Bagheri M, et al. Nanomedicine: Technologies and Applications. Kindle. 2024;4(1):1-196.
260. Farrokhi M, Taheri F, Moeini A, Farrokhi M, Alireza MZS, Farahmandsadr M, et al. Artificial Intelligence for Remote Patient Monitoring: Advancements, Applications, and Challenges. Kindle. 2024;4(1):1-261.
261. Farrokhi M, Taheri F, Moeini A, Farrokhi M, Khouzani PJ, Ghadirzadeh E, et al. Artificial Intelligence for Drug Development, Personalized Prescriptions, and Adverse Event Prediction. Kindle. 2024;4(1):1-180.
262. Karimian S, Taheri F, Farrokhi M, Farrokhi M, Bayat Z, Zadeh SAM, et al. Digital Health and Wearable Technologies. Kindle. 2024;4(1):1-240.
263. Khorsand M-S, Heidari S, Darbani R, Tosi YEK, Pourasad MH, Rajabloo Y, et al. AI Chatbots and Telemedicine in Cancer Care: Supporting Patients and Enhancing Communications. Kindle. 2024;4(1):1-205.
264. Nemati P, Khalaji A, Rajabloo Y, Kazemi MH, Nouri S, Mohebbi S, et al. AI and Deep Learning in

Understanding the Etiology and Pathogenesis of Cancers. Kindle. 2024;4(1):1-173.
265. Rahmani E, Farrokhi M, Nemati P, Riahi S, Rostami ME, Golafzani RS, et al. Global Health Challenges. Kindle. 2024;4(1):1-218.
266. Rigi A, Harati K, Abbaspour M, Fattahpour SF, Hosseini P, Fard AM, et al. AI and Deep Learning in Understanding the Etiology and Pathogenesis of Autoimmune Diseases. Kindle. 2024;4(1):1-182.
267. Taheri F, Farrokhi M, Rajabloo Y, Razavi N, Shirdel E, Hooshiar MH, et al. Complementary and alternative medicine (CAM). Kindle. 2024;4(1):1-193.
268. Zahmatkesh N, Babaei SS, Manesh SH, Abbaspour M, Ghadirzadeh E, Salimian N, et al. Artificial Intelligence for Prediction of Metastasis Risk and Survival. Kindle. 2024;4(1):1-205.
269. Rahmani E, Farrokhi M, Aghajan A, Gholampour G, Ghoodjani E, Shemshadigolafzani R, et al. AI-Driven Strategies for Improving Patient Quality of Life. Kindle. 2025;5(1):1-214.
270. Rezaei M, Azarshab M. Research Hotspots and Global Mapping of Publications in the Role of Artificial Intelligence in Cancer: A Bibliometric Study. Journal of Reviews in Medical Sciences. 2024;4(1):1-10.

Proof